WO1990005730A2 - Novel cyclobutane derivative and process for producing same - Google Patents

Novel cyclobutane derivative and process for producing same Download PDF

Info

Publication number
WO1990005730A2
WO1990005730A2 PCT/JP1989/001190 JP8901190W WO9005730A2 WO 1990005730 A2 WO1990005730 A2 WO 1990005730A2 JP 8901190 W JP8901190 W JP 8901190W WO 9005730 A2 WO9005730 A2 WO 9005730A2
Authority
WO
WIPO (PCT)
Prior art keywords
bis
group
cyclobutane
compound
general formula
Prior art date
Application number
PCT/JP1989/001190
Other languages
French (fr)
Other versions
WO1990005730A3 (en
Inventor
Yuh-Ichiro Ichikawa
Aya Narita
Kaoru Matsuo
Keiko Aoyama
Fumiko Matsumura
Yukihiro Nishiyama
Kenichi Matsubara
Takemitsu Nagahata
Hiroo Hoshino
Jun-Ichi Seki
Koichi Narasaka
Yujiro Hayashi
Original Assignee
Nippon Kayaku Kabushiki Kaisha
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nippon Kayaku Kabushiki Kaisha filed Critical Nippon Kayaku Kabushiki Kaisha
Priority to GB9015942A priority Critical patent/GB2232669B/en
Priority to DE19893991368 priority patent/DE3991368T1/en
Publication of WO1990005730A2 publication Critical patent/WO1990005730A2/en
Priority to SE9002445A priority patent/SE501370C2/en
Publication of WO1990005730A3 publication Critical patent/WO1990005730A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/553—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms with halogen atoms or nitro radicals directly attached to ring carbon atoms, e.g. fluorouracil
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/28—Oxygen atom
    • C07D473/30—Oxygen atom attached in position 6, e.g. hypoxanthine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Definitions

  • This invention relates to cyclobutane deriva ⁇ tives expectedly useful as medical drugs such as antiviral 5 agent, carcinostatic agent and the like, as well as to their useful production intermediates and a process for producing them.
  • nucleic acid-related substances are 0 known to have an antiviral activity or a carcinostatic activity, and some of them are clinically used as useful medical drugs.
  • Vidarabine M. Privat de Garilhe and J. de Rubber, C. R. Acad. Soc. D (Paris) 259, 2725 (1964)
  • Aciclovir G. B. Elion et al., Proc. Natl. 5 Acad. Sci. USA, 74, 5716 (1977)
  • Azidothymidine H. Mitsuya et al., Proc. Natl. Acad. Sci.
  • antiviral agents are known as antiviral agents
  • 5-Fluorouracil and cytosine arabin ⁇ side are known as carcinostatic agents.
  • the above-mentioned antiviral agents 0 are not widely applicable and limited in the method of administration because of their solubility, oral absorb ⁇ ability and influence on metabolism. Further, they have many problems such as difficulty of longterm administra ⁇ tion because of side reactions such as bone marrow *-> supression. Further, because of the increasing tendency of malignant viral diseases such as acquired immuno ⁇ deficiency syndrome (AIDS), T cell leukemia in-the adult (ATL) , etc., development of new excellent antiviral drug is desired.
  • the above-mentioned carcinostatic agents also have many unsolved problems regarding applicability and side reaction, etc.
  • This invention relates to cyclobutane deriva- tives represented by the following general formula (IV) :
  • B represents a nucleic acid base and R 4 represents hydrogen atom or a protecting group.
  • pyrimidine base and purin ⁇ base can be referred to.
  • examples of the pyrimidine base include the compounds represented by the following formulas:
  • Y represents hydrogen atom
  • Y represents hydrogen atom
  • Y represents hydrogen atom
  • Y represents hydrogen atom or amino group.
  • the compounds represented by general formula (IV) can be produced by reacting a compound represented by the following general formula (V) :
  • R represents hydrogen atom or a protecting group and B represents a nucleic acid base
  • any group may be used without limitation so far as it is conventionally used as a protecting group.
  • the protecting group R include ester type protecting groups such as acyl groups (e.g. acetyl, benzoyl and the like) and carbamoyl groups (e.g. dimethylcarbamoyl, diphenylcarbamoyl and the like), ether type protecting groups such as silyl groups (e.g. t-butyldimethylsilyl, t-butyldiphenylsilyl and the like),
  • (C,-C 4 ) alkoxy-(C 1 -C 4 ) alkyl groups e.g. methoxymethyl and the like
  • benzyl group and the like.
  • Examples of the leaving group X in general formula (V) include sulfonyloxy groups such as methanesulfonyloxy, p-toluene- sulfonyloxy, trifluoromethanesulfonyloxy and the like, and halogen atoms such as chlorine, bromine, iodine and the like.
  • nucleic acid base examples include pyrimidine bases such as uracil, thymine, cytosine, 5-fluorouracil and the like, and purine bases such as adenine, hypoxanthine, guanine, 2-amino-6-chloropurine, 2-aminopurine, 2,6-diaminopurine and the like. These compounds may have a protecting group.
  • pyrimidine bases such as uracil, thymine, cytosine, 5-fluorouracil and the like
  • purine bases such as adenine, hypoxanthine, guanine, 2-amino-6-chloropurine, 2-aminopurine, 2,6-diaminopurine and the like.
  • purine bases such as adenine, hypoxanthine, guanine, 2-amino-6-chloropurine, 2-aminopurine, 2,6-diaminopurine and the like.
  • These compounds may have
  • R is as defined above;
  • R 5 represents C,-Cc lower alkyl group such as benzyl, butyl and the like, (C ⁇ -Cg alkoxy)-(C,-C 5 alkyl) group such as methoxyethyl and the like, or R ;
  • R represents hydrogen atom, halogen atom or NHR 4;
  • R7 represents hydrogen atom or NHR 4;
  • Y1 represents hydrogen atom, halogen atom or
  • the ratio between the compound of general formula (V) and the compound of general formula (XII)-(XVII) is recommendably about 0.5 to about 10 equivalents and more preferably about 1 to about 5 equivalents of the latter compound per 1 equivalent of the former compound.
  • This reaction is carried out either in the presence of a basic catalyst or in the absence of catalyst.
  • basic catalyst potassium carbonate, lithium hydride, sodium hydride and the like can be used.
  • the reaction is carried out in a solvent such as N,N-dimethylformamide (DMF), dimethyl sulfoxide (DMSO) , l,3-dimethyi-2-imidazolinone, hexamethyl phosphoric triamide (HMPA) and the like, at a temperature ranging from 0°C to reflux temperature of the solvent, preferably from ambient temperature to about 170°C.
  • a solvent such as N,N-dimethylformamide (DMF), dimethyl sulfoxide (DMSO) , l,3-dimethyi-2-imidazolinone, hexamethyl phosphoric triamide (HMPA) and the like.
  • the basic catalyst is recommendably used in an amount of 0 to 2 equivalents, preferably 0.5 to 1.5 equivalents, and more preferably about 0.8 to 1.2 equivalents.
  • Elimination of the protecting group (including alkyl group) from the compound of general formula (VI) can be achieved by using appropriate protecting group- eliminating reagent and protecting group-eliminating method in accordance with the kind of protecting group.
  • the protecting group-eliminating reagent alkalis such as sodium hydroxide, sodium methylate, ammonia and the like, acids such as hydrochloric acid, sulfuric acid and the like, fluorinated reagent such as tetrabutylammonium fluoride, and the like can be referred to, for example.
  • the protecting group-eliminating method hydrogenolysis and the like can be referred to, for example.
  • Y represents hydrogen atom, halogen atom or amino group
  • hydroxyl group of a guanine derivative represented by general formula (IVa) is protected to prepare a compound represented by general formula (XX), after which it is reacted with a halogenating agent such as phosphorus oxychloride and the like or a sulfonylating agent such as 1,3,5-trimethylbenzenesulfonyl chloride and the like to synthesize a compound represented by general formula (XXI).
  • a halogenating agent such as phosphorus oxychloride and the like or a sulfonylating agent such as 1,3,5-trimethylbenzenesulfonyl chloride and the like
  • XXI 1,3,5-trimethylbenzenesulfonyl chloride and the like
  • an adenine derivative of general formula (IVc) is diazotized by, for example, a treatment with nitrous acid and thereafter hydrolyzed or treated with a hydrolyzing enzyme such as Adenosine deaminase or the like, whereby a compound represented by general formula (IVd) can- be obtained.
  • R 4 represents hydrogen atom or a protecting group
  • X represents an leaving group
  • a compound of general formula (V) is treated with an azide ion compound such as sodium azide or the like and there ⁇ after reduced in the usual way to synthesize an amine derivative represented by general formula (XXII), and the latter (XXII) is converted to a compound of general formula (IV) via an intermediate represented by general formula (XXIII) according to the known method (R. Vince et al., J. Med. Chem., 22, 1358 (1984); R. Vince et al., J. Med. Chem., , 2026 (1987); Y. F. Shealy and C. A. O'Dell, J.
  • R represents an alkyl group having 1 to 5 carbon atoms or an aralkyl group or, taken in conjunction of two R groups, represents a cyclic alkylene group having 2 to 3 carbon
  • R represents hydrogen atom, alkyl group having 1 to 5 carbon atoms, protected hydroxyalkyl group or
  • R represents hydrogen atom, lower alkyl group having 1 to 5 carbon atoms, lower alkoxy group having 1 to 5 carbon atoms or aralkyloxy group
  • A represents a straight or branched chain alkylene group having 2 to 5 carbon atoms
  • Y represents oxygen atom or sulfur atom
  • Z represents substituented or unsubsti- tuted methylene group, oxygen atom or sulfur atom
  • a compound of general formula (I) and a compound of general formula (II) are reacted in the presence of a condensation catalyst, whereby a cyclobutane compound represented by general formula (III) is obtained in a high yield and this product is racemic or optically active in accordance with the kind of the catalyst.
  • Lewis acids and combinations of a Lewis acid and an equivalent or excessive amount of a ligand can be referred to, for example.
  • said Lewis acid include titanium compounds such as titanium tetrachloride, dichlorodiisopropoxytitaniu and the like, tin compounds such as stannous chloride, stannic chloride, stannous trifluoromethansulfonate or the like, and aluminum compounds such as dimethylaluminum chloride, diethylaluminum chloride and the like.
  • ligand sterically complicated diols are preferable.
  • Examples of said ligand include compounds having a ring not smaller than 5-membered ring (preferably 5- to 8-merabered ring) in molecule and two hydroxy-containing groups in both sides of the ring, such as (2S,3S)-2,3-0-(1-phenylethylidene)- l,l,4,4-tetraphenyl-l,2,3,4-butanetetraol (Compound A), (2 ,3R)-2,3-0-(1- ⁇ henylethylidene)-1,1,4,4-tetra ⁇ henyl- 1,2,3,4-butanetetraol (Compound B) , (2S,3S)-2,3-0- benzylidene-1,1,4,4-tetraphenyl-1,2,3,4-butanetetraol (Compound C) , (2R,3R)-2,3-0-benzylidene-l,1,4,4-tetra- phenyl-l,2,3,4-butanet
  • This reaction can sometimes be made to progress more efficiently by adding a dehydrating agent such as Molecular Sieves 4A and the like into the reaction system.
  • a dehydrating agent such as Molecular Sieves 4A and the like
  • the solvent usable in this reaction include hydrocarbon solvents such as pentane, hexane, heptane, petroleum ether, benzene, toluene, ethylbenzene, trimethylbenzene, triisopropylbenzene and the like; halogenated hydrocarbon solvents such as Flon and the like; ethereal solvents such as ether, tetrahydrofuran and the like; acetonitrile; and mixtures of these solvents.
  • the reaction temperature is recommendably in the range from freezing point of reaction solvent to its boiling point, and preferably in the range of -50°C to about 30°C. For example, by reacting one equivalent of a
  • examples of the alkyl group having 1 to 5 carbon atoms represented by R 1 , R 2 and R 3 include alkyl groups such as methyl, ethyl, butyl and the like;
  • examples of the aralkyl group include alkyl groups substituted by an aromatic ring such as benzyl group, 4-methoxybenzyl group and the like;
  • examples of the protected hydroxyalkyl group include benzyloxy- methyl group, acetyloxymethyl group, t-butyldiphenyl- silyloxymethyl group and the like;
  • examples of the protected carboxyl group include alkoxycarbonyl groups such as methoxycarbonyl, ethoxycarbonyl and the like and aralkyloxycarbonyl groups such as benzyloxycarbonyl and the like;
  • examples of the alkoxy group having 1 to 5 carbon atoms include methoxy group, allyloxy group and the like; and examples of the aralkyloxy group include benzy
  • examples of the compound represented by general formula (III) include the compounds of general formula (III) wherein R 1, R2, R3, A, Y and Z are as shown in Table 1:
  • the compounds represented by general formula (V) can be produced, for example, from a compound represented by general formula (V).
  • Reaction Scheme (5) (in this reaction scheme, R is the same as in general formula (III) , R and R each represents hydrogen atom, alkyl group having 1 to 5 carbon atoms or aralkyl
  • R represents hydrogen atom or a protecting group
  • X represents an eliminable group
  • a compound of general formula (IX) is protected to obtain a compound of general formula (IX), and its dithioketal part is hydrolyzed in an aqueous solvent with a halogenating agent such as iodine, N-bromo- succinimide, N-chlorosuccinimide, sulfuryl chloride and the like or a heavy metal compound such as silver nitrate, silver oxide, silver perchlorate, mercury chloride, copper chloride, copper oxide and the like or a combination of these compounds to form a ketone compound represented by general formula (X) .
  • a halogenating agent such as iodine, N-bromo- succinimide, N-chlorosuccinimide, sulfuryl chloride and the like or a heavy metal compound such as silver nitrate, silver oxide, silver perchlorate, mercury chloride, copper chloride, copper oxide and the like or a combination of these compounds to form a ketone compound represented by general formula (X
  • a compound represented by general formula (X) is reduced with a metal-hydrogen complex compound such as lithium aluminum hydride, lithium tri(t-butoxy)-aluminum hydride, sodium boron hydride, lithium tri(s-butyl)-boron hydride, lithium boron hydride and the like or a metal hydride such as di-isobutyl-aluminum hydride, diborane and the like as a reductant, in a solvent such as hydrocarbon type solvent (e.g. pentane, hexane, heptane, petroleum ether, benzene, toluene, ethylbenzene and the like), halogenated hydrocarbon type solvent (e.g.
  • hydrocarbon type solvent e.g. pentane, hexane, heptane, petroleum ether, benzene, toluene, ethylbenzene and the like
  • halogenated hydrocarbon type solvent
  • R represents hydrogen.atom or a protecting group
  • a 1,2-trans alcohol represented by general formula (Xlb) is selectively formed.
  • a 1,2-cis alcohol represented by general formula (XIa) is preferentially formed.
  • stereoisomers obtained herein i.e. the compound of general formula (XIa) and the compound of general formula (Xlb), after isolation, are both easily convertible from one to the other.
  • a compound represented by general formula (XIa) or a compound represented by general formula (Xlb) is again oxidized to a ketone represeted by general formula (Xa) by means of conventional oxidant or oxidizing method (for example, metal oxidizing agent such as chromic acid/acetic acid, chromic acid/pyridine and the like, or dimethyl sulfoxide (DMSO)-oxidation method such as DMSO-acetic anhydride/acetic acid, DMSO-oxalyl chloride-triethylamine/ methylene chloride and the like) , after which the oxidized product (Xa) is subjected to a selective reduction.
  • metal oxidizing agent such as chromic acid/acetic acid, chromic acid/pyridine and the like
  • a compound represented by general formula (XIa) or (Xlb) is reacted with a trivalent phosphorus compound such as triphenylphosphine, trimethyl phosphite, triethyl phosphite ot the like, a carboxylic acid such as acetic acid, benzoic acid or the like, and an azodicarboxylic ester such as diethyl azodicarboxylate or the like, in a solvent such as hydrocarbon type solvent (e.g. pentane, hexane, heptane, petroleum ether, benzene, toluene, ethylbenzene and the like) , halogenated hydrocarbon solvent (e.g.
  • a solvent such as hydrocarbon type solvent (e.g. pentane, hexane, heptane, petroleum ether, benzene, toluene, ethylbenzene and the like) , hal
  • ethereal solvent e.g. ether. tetrahydrofuran and the like
  • reaction temperature preferably -50°C to 30°C
  • the ester is hydrolyzed with an alkali such as potassium carbonate, sodium hydroxide, sodium methylate, ammonia and the like or an acid such as hydrochloric acid, sulfuric acid and the like or reduced with a metal-hydrogen complex compound such as lithium aluminum hydride, lithium tri(s-butyl)-boron hydride, lithium boron hydride and the like or a metal hydride such as di-isobutyl-aluminurn hydride, diborane and the like.
  • an alkali such as potassium carbonate, sodium hydroxide, sodium methylate, ammonia and the like or an acid such as hydrochloric acid, sulfuric acid and the like
  • a metal-hydrogen complex compound such as lithium aluminum hydride, lithium tri(s-butyl)-boron hydride, lithium boron hydride and the like or a metal hydride such as di-isobutyl-aluminurn hydride, diborane and the like.
  • a 6-well multi-plate having a single layer of Vero cell (derived from the kidney cell of African Green-Monkey was infected with 100 to 150 PFU (plaque forming units) of virus. After adsorption at 37°C for one hour, a layer of agar medium (Eagle MEM medium containing 1.5% of agar) containing a varied concentration of sample was superposed thereon, and a cultivation was carried out at 37°C for 48 hours in 5% (v/v) carbon dioxide incubator. The formation of plaque was measured, from which 50% inhibitory value (IC_ 0 ) was determined.
  • Vero cell derived from the kidney cell of African Green-Monkey was infected with 100 to 150 PFU (plaque forming units) of virus. After adsorption at 37°C for one hour, a layer of agar medium (Eagle MEM medium containing 1.5% of agar) containing a varied concentration of sample was superposed thereon, and a cultivation was carried out at 37°C for 48 hours in 5% (v
  • HCMV HCMV belonging to DNA virus
  • Anti-HCMV activity was determined in the following manner.
  • a 35 mm dish having a single layer of human embryonal fibroblast was infected with 100 PFU of HCMV (A0169 strain) .
  • a medium (0.5% agarose, 2% fetal calf serum) containing a varied concentration of sample compound was superposed thereon, and cultivation was carried out at 37°C for 10 days in 5% (v/v) carbon dioxide incubator. Then, formation of plaque was measured, from which 50% inhibitory value (IC 5Q ) was determined.
  • Antiviral activity against B hepatitis virus (HBV) belonging to DNA virus was examined by the following method. (Method 3) According to the procedure of Dulbecco (Proc.
  • cultured liver cell strain HB611 producing and releasing active B hepatitis virus was cultured in a modified Eagle medium (GIBCO) at 37°C at a C0 2 concentration of 5% in the presence of 10% fetal calf serum, 200 micrograms/ml of G418, 100 ⁇ /ml of Penicillin and 100 ⁇ /ml of Streptomycin.
  • the culture fluid was inoculated onto a 6-well plate at a rate of 5 x 10 cells/well (35 mm).
  • MT-4 cell (about 50,000 cells/ml) was introduced into a 24-well tray, to which was added 100 micrograms of a solution containing a predetermined quantity of sample compound. Culture was carried out at 37°C for 2 hours in 5% (v/v) carbon dioxide incubator. Then, 10 3 to 104
  • infection units of HIV was added and cultured for 4 days, after which a part of the culture fluid was applied onto a slide glass and immobilized with acetone and development of virus antigen was tested by fluorescent antibody method.
  • HeLa S 3 cell was made into a suspension (7.5 x
  • 3% HCl was added at a rate of 0.2 ml/well and the resulting mixture was sealed and allowed to stand at room temperature for about 24 hours, to extract pigment from the cells.
  • Optical absorbance of each well at 660 nm was measured by means of Dynatic Microplate Reader, from which growth inhibitory rate (%) at varied concentration was calculated according to the following equation. The results were plotted on a logarithmic probability paper, from which .50% inhibitory concentration (IC 5Q , micrograms/ml) was determined.
  • N_ cell number at the start of culture
  • N_, Cell number in control group
  • the compounds of this invention represented by general formula (IV) are expected to be effectively usable for controlling a number of viral diseases such as herpes labialis, . herpes in the genital organs, herpes zoster, simple infection from Herpesvirus 1 and 2 (HSV-I, II), Varicells zoster virus (VZV) , Cytomegalovirus (CMV) and Epstein-Barr virus (EBV) , viral hapatitis, viral respiratory diseases, viral diseases of the digestive organs, AIDS, ATL, etc.
  • viral diseases such as herpes labialis, . herpes in the genital organs, herpes zoster, simple infection from Herpesvirus 1 and 2 (HSV-I, II), Varicells zoster virus (VZV) , Cytomegalovirus (CMV) and Epstein-Barr virus (EBV) , viral hapatitis, viral respiratory diseases, viral diseases of the digestive organs, AIDS,
  • the compounds of this invention obtained in the above-mentioned manner as an antiviral or carcinostatic drug, they can be administered orally, intravenously or percutaneously to the warm-blood animal. Though the dose may vary dependent on symptoms and age of the warm-blood animal and the method of administration. it is usually 0.1 to 500 mg/kg/day.
  • the compounds of this invention are administered in the form of a composition prepared by mixing them with appropriate excipients. As the form of composition, tablet, granule, powder, capsule, injection, cream, suppository, and the like can be used. Next, production of the compounds of this invention will be concretely illustrated by way of the following examples.
  • TMB 1,3,5- trimethylbenzene
  • a saturated aqueous solution of sodium hydrogen carbonate was added to the reaction mixture, the inorganic matter was filtered off with Celite, and the organic matter was extracted with ethyl acetate.
  • the extract solution was washed with saturated aqueous solution of sodium chloride and dried over anhydrous sodium sulfate, and the solvent was distilled off under reduced pressure.
  • dichloroisopro- poxytitanium 125 mg, 0.53 mmol
  • (2R,3R)-2,3-0- (1-phenylethylidene)-1,1,4,4-tetraphenyl-l,2,3,4- butanetetraol Compound B
  • toluene 5 ml
  • a part (0.5 ml, 00.053 mmol) of the resulting solution was taken out and added to powdery Molecular Sieves 4A (100 mg) , and toluene (1.5 ml) was added thereto.
  • Example 3 Production of (+)-(2R,3R)-3-Methoxycarbonyl- 1,1-bis(methylthio)-2-(oxazolidin-2-one-3-yl)- carbonylcyclobutane
  • the following table illustrates the results of a study on the conditions in the production of this compound (including Example 2).
  • the other conditions and methods of treatment were the same as in Example 1 or 2.
  • Oxz is oxazolidin-2-one-3-yl group.
  • Optical purity was determined from NMR of bis-MTPA ester of Compound (VII).
  • TMB means 1,3,5-trimethylbenzene.
  • T-PE means toluene-petroleum ether.
  • Example 5 Production of ( ⁇ )-(2S,3S)-2,3-Bis(methoxy- carbonyl)-!,1-bis(methylthio)-cyclobutane
  • Example 5-1 In an atmosphere of argon gas, lM-dimethoxy- magnesium/methanbl (25 ml, 25 mmol) was added to a methanolic solution (25 ml) of (-)-(2S,3S)-3-methoxy- carbonyl-1,l-bis(methylrhio)-2-(oxazolidin-2-one-3-yl)- carbonylcyclobutane (3.94 g, 12.3 mmol) obtained in Example 1-1 and stirred at room temperature for one hour.
  • Example 6 production of (+)-(2R,3R)-2,3-Bis(methoxy- carbonyl)-1,1-bis(methylthio)-cyclobutane
  • (+)-(2R,3R)-3-methoxycarbonyl-l,l-bis- (methylthio)-2-(oxazolidin-2-one-3-yl)carbonylcyclobutane produced in Example 2 was used as the starting compound.
  • (+)-(2R,3R)-2,3-bis(methoxycarbonyl)-l,l-bis- (methylthio)cyclobutane was obtained in a yield of 95%.
  • This compound had an optical purity of 98% ee (cf. Example 9).
  • Example 6 The procedure of Example 6 was repeated, except that the (+)-l,1-bis(methylthio)-2-(oxazolidin-2-on-- 3-yl)-carbonylcyclobutane produced in Example 4 was used as the starting compound.
  • (+)-2-methoxycarbonyl- 1,1-bis(methylthio)cyclobutane was obtained in a yield of 83%.
  • This compound had an optical purity of 88% ee (cf. Example 10) .
  • Example 8 Production of (-)-(2S,3S)-2,3-Bis(hydroxy- methyl)-1,1-bis(methylthio)cyclobutane
  • an ethereal solution (10 ml) of (-)-(2S,3S)-2,3-bis(methoxycarbonyl)- 1,1-bis(methylthio)cyclobutane (1.96 g, 7.4 mmol) produced in Example 5-1 was slowly added to an ethereal suspension of lithium aluminum hydride (562 mg, 14.8 mmol) at 0°C, and the resulting mixture was stirred at 0°C for 2 hours.
  • lithium aluminum hydride 562 mg, 14.8 mmol
  • Example 9 Production of (+)-(2R,3R)-2,3-Bis(hydroxy ⁇ methyl)-1,1-bis(methylthio)-cyclobutane
  • (+)-(2R,3R)-2,3-bis(methoxycarbonyl)-1,1-bis- (methylthio)cyclobutane produced in Example 6 was used.
  • (+ )"-(2R,3R)-2,3-bis(hydroxymethyl)-l,l-bis(methyl- thio)cyclobutane was obtained in a yield of 70%.
  • NMR and IR of this compound were identical with those of the compound f Example 8.
  • Example 10 Production of (+)-2-Hydroxymethyl-l,1-bis- methylthio)cyclobutane The procedure of Example 8 was repeated, except that (+)-2-methoxycarbonyl-l,1-bis(methylthio)cyclobutane obtained in Example 7 was used. Thus, (+)-2-hydroxy- methyl-1,1-bis(methylthio)cyclobutane was obtained in a yield of 54%.
  • Example 11 Production of (+)-(2S,3S)-2,3-Bis(t-butyl- diphenylsilyloxymethyl)-1,1-bis(methylthio)- cyclobutane
  • (-)-(2S,3S)-2,3-bis(hydroxymethyl)-l,l-bis(methylthio)- cyclobutane (1.37 g, 6.58 mmol)
  • triethylamine 2.8 ml, 20 mmol
  • 4-dimethylaminomethylpyridine catalytic amount and DMF (1 ml).
  • t-butyldiphenylsilyl chloride (4.52 g, 25 mmol) was added to the solution and stirred at room temperature overnight. After concentrating the reaction mixture under reduced pressure, the concentrate was dissolved into ether, washed with saturated aqueous solution of sodium chloride and dried over anhydrous sodium sulfate.
  • Example 12 Production of (-)-(2R,3R)-2,3-Bis(t-butyl- diphenylsilyloxymethyl)-l,1-bis(methylthio)- cyclobutane t-Butyldiphenylsilyl chloride (292 mg, 1.06 moles) was added to a solution of (+)-(2R,3R)-2,3-bis- (hydroxymethyl)-l,l-bis(methylthio)cyclobutane (82 mg, 0.39 mmol), imidazole (106 mg,. 1.55 mmol) and 4-dimethylaminomethylpyridine (catalytic amount) in DMF (4 ml), and the resulting mixture was stirred at room temperature overnight.
  • (+)-(2R,3R)-2,3-bis- (hydroxymethyl)-l,l-bis(methylthio)cyclobutane 82 mg, 0.39 mmol
  • imidazole 106 mg,. 1.55 mmol
  • Example 13 Production of (+)-(2S,3S)-2,3-Bis(t-butyl ⁇ diphenylsilyloxymethyl)-1-cyclobutanone N-Chlorosuccinimide (1.60 g, 12 mmol) and silver nitrate (2.29 g, 13.5 mmol) were dissolved into 80% aqueous solution of acetonitrile (45 ml) , to which was rapidly added at 25°C a solution of (+)-(2S,3S)-2,3-bis- (t-butyldiphenylsilyloxymethyl)-1,1-bis(methylthio)- cyclobutane (2.06 g, 3 mmol) in a mixture consisting of acetonitrile (6 ml) and methylene chloride (1 ml).
  • Example 14 Production of (-)-(2R,3R)-2,3-Bis(t-butyl- diphenylsilyloxymethyl)-l-cyclobutanone The procedure of Example 13 was repeated, except that (-)-(2R,3R)-2,3-bis(t-butyldiphenylsilyloxy ⁇ nethyl)- 1,1-bis(methylthio)-cyclobutane was used.
  • lithium tri(t-butoxy)-aluminum hydride (1.27 g, 5.0 mmol) was added to tetrahydrofuran (THF) (10 ml) and cooled to -78°C.
  • THF tetrahydrofuran
  • (+)-(2S,3S)-2,3-bis(t-butyldiphenylsilyloxymethyl)-1- cyclobutanone (1.21 g, 2.0 mmol) in THF, and temperature of the mixture was slowly elevated to room temperature with stirring over a period of several hours.
  • methylene chloride was added and the inorganic matter was filtered off.
  • Example 15-3 Transformation from (+)-(lR,2S,3S)-2,3-Bis- (t-butyldiphenylsilyloxymethyl)-cyclobutanol to (+)-(IS,2S,3S)-2,3-Bis(t-butyldiphenyl ⁇ silyloxymethyl)cyclobutanol Step 1
  • diethyl azodicarboxylate (217 microliters, 1.38 mmol) was added to a solution of (+)-(lR,2S,3S)-2,3-bis(t-butyldiphenyl- s ' ilyloxymethyl)cyclobutanol (700 mg, 1.15 mmol), benzoic acid (167 mg, 1.37 mmol) and triphenylphosphine (362 mg, 1.38 mmol) in benzene (10 ml), and the resulting mixture was stirred at room temperature overnight.
  • Example 16 Production of (+)-(lR,2S,3S)-2,3-Bis(t-butyl- diphenylsilyloxymethyl)-l-methanesulfonyloxy- cyclobutane Methanesulfonyl chloride (0.17 ml, 2.2 mmol) was added at 0°C to a solution of (+)-(lR,2S,3S)-2,3-bis- (t-butyldiphenylsilyloxymethyl)cyclobutanol (911 mg, 1.5 mmol) and triethylamine (0.6 ml, 4.3 mmol) in methylene chloride, and the mixture was stirred at 0°C for 15 • minutes.
  • Step 2 Production of (-)-9-[(lS,2R,3S)-2,3-bis(hydroxy- methyl)cyclobutane-l-yl]-adenine (Compound 2)
  • Step 2 Production of (-)-9-[(lS,2R,3S)-2,3-bis(hydroxy- methyl)cyclobutane-l-yl]-guanine (Compound 5) 2 N hydrochloric acid (1 ml) was added to (-)-2-amino-9-[(IS,2R,3S)-2,3-bis(t-butyldiphenyIsilyloxy- methyl)cyclobutane-l-yl]-6-(2-methoxyethoxy)-purine (140 mg, 0.17 mmol) obtained in Step 1, and the mixture was heated under reflux for one hour. After distilling off the solvent from the reaction mixture under reduced pressure, water was added and the ether-soluble substances were removed.
  • UV ⁇ max (H 2 0) nm pH l,253,279(sh); pH 7,252,272(sh); pH I3,257(sh), 267.
  • Example 19 Production of (+)-(lS,2S,3S)-2,3-Bis(t-butyl- diphenylsilyloxymethyl)-l-methanesulfonyloxy- cyclobutane
  • the treatment of Example 16 was repeated, except that (+)-(IS,2S,3S)-2,3-bis(t-butyldiphenylsilyloxy ⁇ methyl)cyclobutanol was used.
  • (+)-(lS,2S,.3S)-2,3- bis(t-butyldiphenylsilyloxymethyl)-methanesulfonyloxy- cyclobutane was obtained in a quantitative yield.
  • Step 2 Production of (-)-9-[(lR,2R,3S)-2,3-bis(hydroxy- methyl)cyclobutane-l-yl]-adenine (Compound 8) To methanolic solution (2 ml) of (+)-9-
  • Lithium hydride (6 mg, 0.75 mmol) was added to a suspension of 2-amino-6-(2-methoxyethoxy)-purine (155 mg, 0.74 mmol) in DMF (4 ml), and the mixture was stirred for one hour. Then, a solution of (+)-(lS,2S,3S)-2,3-bis- (t-butyldiphenylsilyloxymethyl)-l-methanesulfonyloxy- cyclobutane (450 mg, 0.65 mmol) in DMF (1.5 ml) was added to the reaction mixture and stirred at 145°C for 6 hours.
  • Step 2 Production of (+)-9-[(lR,2R,3S)-2,3-bis(hydrozy- methyl)cyclobutane-1-yl]-guanine (Compound 11)
  • Step 2 Production of (lR,2R,3S)-l-amino-2,3-bis(t-butyl- diphenylsilyloxymethyl)cyclobutane
  • Example 23 Production of l-[(lR,2R,3S)-2,3-Bis(hydroxy- methyl)cyclobutane-1-yl]-5-methyl-2,4(IH,3H)- pyrimidindione (Compound 29)
  • Step 1 Production of N-[[(1R,2R,3S)-2,3-bis(t-butyl ⁇ diphenylsilyloxymethyl)cyclobutyl]amino- carbonyl]-3-methoxy-2-methylacrylamide
  • a suspension of 3-methoxy-2-methylacrylic acid chloride (673 mg, 5 mmol) and silver cyanate .(1.50 g, 10 mmol) in anhydrous benzene (10 ml) was heated under reflux for one hour, and then allowed to stand at room temperature.
  • Step 2 Production of l-[(lR,2R,3S)-2,3-bis(hydroxy- methyl)cyclobutan-1-yl]-5-methyl-2,4(IH,3H)- pyrimidindione (Compound 29) lM-Tetrabutylammonium fluoride/THF (2.4 ml, 2.4 mmol) was added to a solution of the N-[[(1R,2R,3S)- 2,3-bis(t-butyldiphenylsilyloxymethyl)cyclobutyl]amino ⁇ carbonyl]-3-methoxy-2-methylacrylamide (590 mg) obtained in Step 1 in methanol (8 ml), and the mixture was stirred overnight at room temperature.
  • methanol 8 ml
  • crushed ice and methylene chloride were added to the residue and stirred at 0 C C for a while, and then it was neutralized with saturated aqueous solution of sodium hydrogen carbonate. After stirring the mixture at 0°C for a while, it was extracted with methylene chloride. The methylene chloride extract solution was dried over anhydrous sodium sulfate, and then the solvent was distilled off.
  • Step 2 Production of 2-amino-9-[(lR,2R,3S)-2,3-bis-
  • UV ⁇ max (H 2 0) nm pH l,244(sh), 313; pH 7,248(sh), 3.6; pH 13,248(sh), 305.
  • Step 2 Production of 2-amino-9-[(lR,2R,3S)-2,3-bis-
  • Example 26 Production of 2,6-Diamino-9-[(lR,2R,3S)- 2,3-bis(hydroxymethyl)cyclobutane-l-yl]- purine (Compound 20) 2-Amino-9-[(IR,2R,3S)-2,3-bis(acetoxymethyl)- cyclobutane-l-yl]-chloropurine (87 mg, 0.24 mmol) was dissolved into methanol (2 ml) and cooled to -78°C. The solution thus obtained was saturated with liquid ammonia, sealed into an ampoule and heated at 100°C for 12 hours.
  • Cyclobutane derivatives of this invention are useful as medical drugs as antiviral agent, carcinostatic agent, a d the like.

Abstract

This invention relates to cyclobutane derivatives represented by general formula (IV), wherein B represents a nucleic acid base and R4 represents hydrogen atom or a protecting group, which is expectedly useful as an antiviral agent or a carcinostatic agent.

Description

TITLE OP THE INVENTION
NOVEL CYCLOBUTANE DERIVATIVE AND PROCESS FOR PRODUCING SAME 1 BACKGROUND OF THE INVENTION
1. Field of the Invention
This invention relates to cyclobutane deriva¬ tives expectedly useful as medical drugs such as antiviral 5 agent, carcinostatic agent and the like, as well as to their useful production intermediates and a process for producing them.
2. Description of the Prior Art
Many of the nucleic acid-related substances are 0 known to have an antiviral activity or a carcinostatic activity, and some of them are clinically used as useful medical drugs. For instance, Vidarabine (M. Privat de Garilhe and J. de Rubber, C. R. Acad. Soc. D (Paris) 259, 2725 (1964)), Aciclovir (G. B. Elion et al., Proc. Natl. 5 Acad. Sci. USA, 74, 5716 (1977) and Azidothymidine (H. Mitsuya et al., Proc. Natl. Acad. Sci. USA, 82, 7096 (1985) are known as antiviral agents, and 5-Fluorouracil and cytosine arabinόside are known as carcinostatic agents. However, the above-mentioned antiviral agents 0 are not widely applicable and limited in the method of administration because of their solubility, oral absorb¬ ability and influence on metabolism. Further, they have many problems such as difficulty of longterm administra¬ tion because of side reactions such as bone marrow *-> supression. Further, because of the increasing tendency of malignant viral diseases such as acquired immuno¬ deficiency syndrome (AIDS), T cell leukemia in-the adult (ATL) , etc., development of new excellent antiviral drug is desired. On the other hand, the above-mentioned carcinostatic agents also have many unsolved problems regarding applicability and side reaction, etc.
SUMMARY OF THE INVENTION
This invention relates to cyclobutane deriva- tives represented by the following general formula (IV) :
Figure imgf000004_0001
wherein B represents a nucleic acid base and R4 represents hydrogen atom or a protecting group.
DETAILED DESCRIPTION OF THE INVENTION
As the nucleic acid base B in the general formula (IV), pyrimidine base and purinό base can be referred to. Examples of the pyrimidine base include the compounds represented by the following formulas:
, and examples of the purine
Figure imgf000004_0002
base include the compounds represented by the
following formulas:
Figure imgf000005_0001
In these formulas, Y represents hydrogen atom
2 or C,_4 lower alkyl group; Y represents hydrogen atom,
3 halogen atom or ammo group; Y represents hydrogen atom
4 or ammo group; and Y represents hydrogen atom or amino group.
Among the compounds represented by general formula (IV), those of which substituents are so configured sterically that substituent B and its adjacent hydroxymethyl group are in a trans relation and the hydroxymethyl group adjacent to B and the other hydroxy¬ methyl group are in a trans relation are preferable, and those having a steric configuration of (IR, 2R, 3S) are more preferable.
Concrete examples of the compound represented by general formula (IV) are shown below. In this specifica¬ tion, relative steric configuration of compounds are expressed in the following manner. Thus,.when the cyclobutane ring is regarded as a plane, a substituent located under the plane (the one side) is designated by sign α, and a substituent located over the plane (the other side) is designated by sign β. 1. (+)-9-[(lα,2α, 3β)-2,3-Bis(hydroxymethyl)cyclo- butane-1-yl]-adenine 2. 9-[(IS,2R,3S)-2,3-Bis(hydroxymethyl)cyclobutane-1- yl]-adenine 3. 9-[(lR,2R,3R)-2,3-Bis(hydroxymethyl)cyclobutane-l- yl]-adenine
4. (+.)-9-[(lα,2α,3β)-2,3-Bis(hydroxymethyl)cyclo- butane-1-yl]-guanine
5. 9-t(IS,2R,3S)-2,3-Bis(hydroxymethyl)cyclobutane-1- yl]-guanine
6. 9-[(IR,2S,3R)-2,3-Bis(hydroxymethyl)cyclobutane-1- yl]-guanine
7. (±)-9-[(lβ,2α,3β)-2,3-Bis(hydroxymethyl)cyclo- butane-1-yl]-adenine 8. 9-[(lR,2R,3S)-2,3-Bis(hydroxymethyl)cyclobutane-l- yl]-adenine 9. 9-[(lS,2S,3R)-2,3-Bis(hydroxymethyl)cylobutane-l-ylJ- adenine
10. (+)-9-[(lβ,2α,3|3)-2,3-Bis(hydroxymethyl)cyclo- butane-l-yl]-guanine
11. 9-[(1R,2R,3S) -2,3-Bis(hydroxymethyl)cyclobutane-1- yl]-guanine
12. 9-[(IS,2S,3R)-2,3-Bis(hydroxymethyl)cyclobu ane-l- yl]-guanine 13. (±)-2-Amino-2-[(lβ,2α,3β)-2,3-bis(hydroxymethyl)- cyclobutane-l-yl]-purine 14. 2-Amino-9-[(IR,2R,3S)-2,3-bis(hydroxymethyl)cyclo- butane-1-yl]-purine 15 . 2-Amino-9- [ ( lS, 2S , 3R) -2 , 3-bis (hydroxymethyl ) cyclo- butane-1-yl]-purine 16. (+)-2-Amino-9-[(lβ,2α,3β)-2,3-bis(hydroxymethyl)- cyclobutane-l-yl]-6-chloropurine 17. 2-Amino-9-[(lR,2R,3S)-2,3-bis(hydroxymethyl)cyclo- butane-1-yl]-6-chloropurine
18. 2-Amino-9-[(IS,2S,3R)-2,3-bis(hydroxymethyl)cyclo- butane-1-yl]-6-chloropurine
19. (±)-2,6-Diamino-9-[(lβ,2α,3β)-2,3-bis(hydroxy- methyl)cyclobutane-1-yl]-purine
20. 2,6-Diarnino-9-[(lR,2R,3S)-2,3-bis(hydroxymethyl)- cyclobutane-1-yl]-purine
21. 2,6-Diamino-9-[(IS,2S,3R)-2,3-bis(hydroxymethyl)- cyclobutane-1-yl]-purine 22. (±)-9-[(lβ,2α,3β)-2,3-Bis(hydroxymethyl)cyclo- butane-1-yl]-hydroxanthine
23. 9-[(1R,2R,3S)-2,3-Bis(hydroxymethyl)cyclobutane-l- yl]-hypoxanthine
24. 9-[(IS,2S,3R)-2,3-Bis(hydroxymethyl)cyclobutane-1- yl]-hypoxanthine
25. (±)-l-[(lβ,2α,3β)-2,3-Bis(hydroxymethyl)cyclo¬ butane-l-yl]-2,4(IH,3H)-pyrimidindione
26. 1-[(1R,2R,3S)-2,3-Bis(hydroxymethyl)cyclobutane-l- yl]-2,4(IH,3H)-pyrimidindione 27. l-[(lS,2S,3R)-2,3-Bis(hydroxymethyl)cyclobutane-l- yl]-2, (IH,3H)-pyrimidindione 28. (+)-l-[(lβ,2α,3β)-2,3-Bis(hydroxymethyl)cyclo- butane-1-yl]-5-methyl-2,4(IH,3H)-pyrimidindione 29. l-[(lR,2R 3S)-2,3-Bis(hydroxymethyl)cyclobutane-l- yl]-5-methyl-2,4(IH,3H)-pyrimidindione 30. 1-[(IS,2S,3R)-2,3-Bis(hydroxymethyl)eyelobutane-l- yl]-5-methy1-2, (1H,3H)pyrimidindione 31. (±)-4-amino-l-[(lβ,2α,3β)-2,3-bis(hydro__ymethyl)- cyclobutane-1-yl]-2(IH)pyrimidinone
32. 4-Amino-l-[(lR,2R,3S)-2,3-bis(hydroxymethyl)cyclo¬ butane-l-yl]-2(IH)-pyrimidinone
33. 4-Amino-l-[(IS,2S,3R)-2,3-bis(hydroxymethyl)cyclo- butane-l-yl]-2(IH)-pyrimidinone
34. (±)-2-AmIno-9-[(lβ,2α,3β)-2,3-bis(acetoxy- methyl)cyclobutane-l-yl]-purine
35. 2-Amino-9-[(lR,2R,3S)-2,3-bis(acetoxymethyl)cyclo- butane-1-yl]-purine 36. 2-Amino-9-[(lS,2S,3R)-2,3-bis(acetoxyτnethyl)cyclo- butane-1-yl)]-purine
Among the compounds of this invention, the compounds represented by general formula (IV) can be produced by reacting a compound represented by the following general formula (V) :
(V)
Figure imgf000008_0001
4 (R represents hydrogen atom or a protecting group and X represents a leaving group.) with a nucleic acid base to obtain a compound represented by the following general formula (VI):
Figure imgf000009_0001
(R represents hydrogen atom or a protecting group and B represents a nucleic acid base) and, when the latter compound has a protecting group, optionally eliminating the protecting group with an appropriate protecting group-eliminating reagent.
4 As the protecting group R in general formula
(V) and (VI), any group may be used without limitation so far as it is conventionally used as a protecting group. Examples of the protecting group R include ester type protecting groups such as acyl groups (e.g. acetyl, benzoyl and the like) and carbamoyl groups (e.g. dimethylcarbamoyl, diphenylcarbamoyl and the like), ether type protecting groups such as silyl groups (e.g. t-butyldimethylsilyl, t-butyldiphenylsilyl and the like),
(C,-C4) alkoxy-(C1-C4) alkyl groups (e.g. methoxymethyl and the like), benzyl group, and the like. Examples of the leaving group X in general formula (V) include sulfonyloxy groups such as methanesulfonyloxy, p-toluene- sulfonyloxy, trifluoromethanesulfonyloxy and the like, and halogen atoms such as chlorine, bromine, iodine and the like.
Examples of the nucleic acid base include pyrimidine bases such as uracil, thymine, cytosine, 5-fluorouracil and the like, and purine bases such as adenine, hypoxanthine, guanine, 2-amino-6-chloropurine, 2-aminopurine, 2,6-diaminopurine and the like. These compounds may have a protecting group. For example, the compounds represented by the following general formulas (XII) to (XVII) can be referred to:
Figure imgf000010_0001
Figure imgf000010_0002
(XV) (XVI) (XVII) (in these formulas, R is as defined above; R5 represents C,-Cc lower alkyl group such as benzyl, butyl and the like, (Cπ-Cg alkoxy)-(C,-C5 alkyl) group such as methoxyethyl and the like, or R ; R represents hydrogen atom, halogen atom or NHR 4; R7 represents hydrogen atom or NHR 4; and Y1 represents hydrogen atom, halogen atom or
C--C5 lower alkyl group) .
In the reaction between a compound represented by general formula (V) and a nucleic acid base (for example, a compound of general formula (XII)-(XVII)) , the ratio between the compound of general formula (V) and the compound of general formula (XII)-(XVII) is recommendably about 0.5 to about 10 equivalents and more preferably about 1 to about 5 equivalents of the latter compound per 1 equivalent of the former compound. This reaction is carried out either in the presence of a basic catalyst or in the absence of catalyst. As basic catalyst, potassium carbonate, lithium hydride, sodium hydride and the like can be used. The reaction is carried out in a solvent such as N,N-dimethylformamide (DMF), dimethyl sulfoxide (DMSO) , l,3-dimethyi-2-imidazolinone, hexamethyl phosphoric triamide (HMPA) and the like, at a temperature ranging from 0°C to reflux temperature of the solvent, preferably from ambient temperature to about 170°C. Based on the amount of the compound of general formula
(XII)-(XVII) , the basic catalyst is recommendably used in an amount of 0 to 2 equivalents, preferably 0.5 to 1.5 equivalents, and more preferably about 0.8 to 1.2 equivalents.
Elimination of the protecting group (including alkyl group) from the compound of general formula (VI) can be achieved by using appropriate protecting group- eliminating reagent and protecting group-eliminating method in accordance with the kind of protecting group. As the protecting group-eliminating reagent, alkalis such as sodium hydroxide, sodium methylate, ammonia and the like, acids such as hydrochloric acid, sulfuric acid and the like, fluorinated reagent such as tetrabutylammonium fluoride, and the like can be referred to, for example. As the protecting group-eliminating method, hydrogenolysis and the like can be referred to, for example.
Among the compounds of this invention represented by general formula (IV), those of-which B is 2,6-diaminopurine, 2-aminopurine or 2-amino-6-halopurine can be produced from a compound represented by the following general formula (IVa), too:
Figure imgf000012_0001
CH20H
Figure imgf000012_0002
Figure imgf000013_0001
Reaction Scheme (1)
(in this scheme, R is as defined above; X represents a
2 leaving group; and Y represents hydrogen atom, halogen atom or amino group) .
For example, as shown in Reaction Scheme (1), hydroxyl group of a guanine derivative represented by general formula (IVa) is protected to prepare a compound represented by general formula (XX), after which it is reacted with a halogenating agent such as phosphorus oxychloride and the like or a sulfonylating agent such as 1,3,5-trimethylbenzenesulfonyl chloride and the like to synthesize a compound represented by general formula (XXI). The compound. (XXI) thus obtained is heated in ampoule together with ammonia-methanol to give a compound of general formula (IVb) wherein Y is amino group. If this compound is catalytically reduced by the use of palladium-carbon catalyst and thereafter the protecting group is eliminated therefrom, there is obtained a compound of general formula (IVb) wherein Y 2 i.s hydrogen atom. Otherwise, by eliminating protecting group from a compound of general formula (XXI) wherein X is halogen atom, there is obtained a compound of general
2 formula (IVb) wherein Y is halogen atom.
The compounds of this invention represented by general formula (IV) wherein B is hypoxanthine can be produced from a compound represented by the following general formula (IVc), too:
Figure imgf000014_0001
CH2OH CH2OH
Reaction Scheme (2)
Thus, as shown in Reaction Scheme (2), an adenine derivative of general formula (IVc) is diazotized by, for example, a treatment with nitrous acid and thereafter hydrolyzed or treated with a hydrolyzing enzyme such as Adenosine deaminase or the like, whereby a compound represented by general formula (IVd) can- be obtained.
Further, the compounds of general formula (IV) can be synthesized in the following manner. Thus, as shown in the following Reaction Scheme (3):
Figure imgf000015_0001
(V) (XXII )
Figure imgf000015_0002
(XXIII) (IV)
(in this reaction scheme, R 4 represents hydrogen atom or a protecting group, X represents an leaving group, B
2 represents a nucleic acid base, and B represents a substituent convertible to B in one step or plural steps) a compound of general formula (V) is treated with an azide ion compound such as sodium azide or the like and there¬ after reduced in the usual way to synthesize an amine derivative represented by general formula (XXII), and the latter (XXII) is converted to a compound of general formula (IV) via an intermediate represented by general formula (XXIII) according to the known method (R. Vince et al., J. Med. Chem., 22, 1358 (1984); R. Vince et al., J. Med. Chem., , 2026 (1987); Y. F. Shealy and C. A. O'Dell, J. Heterocyclic Chem., 12, 1015, (1976); Y. F. Shealy et al., J. Heterocyclic Chem., J ., 383 (1981); etc.) . Further, it was found that a compound represented by general formula (III) is very useful for the production of a compound of general formula (V) or a compound of this invention represented by general formula (IV). Since the compounds of general formula (III) can be obtained in an optically active form, the compounds of general formula (IV) are also obtainable in an optically active form.
Thus, as shown in the following Reaction Scheme (4):
Figure imgf000016_0001
Reaction Scheme (4)
(in this reaction .scheme, R , taken individually, represents an alkyl group having 1 to 5 carbon atoms or an aralkyl group or, taken in conjunction of two R groups, represents a cyclic alkylene group having 2 to 3 carbon
2 atoms; R represents hydrogen atom, alkyl group having 1 to 5 carbon atoms, protected hydroxyalkyl group or
3 protected carboxyl group; R represents hydrogen atom, lower alkyl group having 1 to 5 carbon atoms, lower alkoxy group having 1 to 5 carbon atoms or aralkyloxy group; A represents a straight or branched chain alkylene group having 2 to 5 carbon atoms; Y represents oxygen atom or sulfur atom; and Z represents substituented or unsubsti- tuted methylene group, oxygen atom or sulfur atom), a compound of general formula (I) and a compound of general formula (II) are reacted in the presence of a condensation catalyst, whereby a cyclobutane compound represented by general formula (III) is obtained in a high yield and this product is racemic or optically active in accordance with the kind of the catalyst. As the condensation catalyst usable in this reaction, Lewis acids and combinations of a Lewis acid and an equivalent or excessive amount of a ligand can be referred to, for example. Examples of said Lewis acid include titanium compounds such as titanium tetrachloride, dichlorodiisopropoxytitaniu and the like, tin compounds such as stannous chloride, stannic chloride, stannous trifluoromethansulfonate or the like, and aluminum compounds such as dimethylaluminum chloride, diethylaluminum chloride and the like. As said ligand, sterically complicated diols are preferable. Examples of said ligand include compounds having a ring not smaller than 5-membered ring (preferably 5- to 8-merabered ring) in molecule and two hydroxy-containing groups in both sides of the ring, such as (2S,3S)-2,3-0-(1-phenylethylidene)- l,l,4,4-tetraphenyl-l,2,3,4-butanetetraol (Compound A), (2 ,3R)-2,3-0-(1-ρhenylethylidene)-1,1,4,4-tetraρhenyl- 1,2,3,4-butanetetraol (Compound B) , (2S,3S)-2,3-0- benzylidene-1,1,4,4-tetraphenyl-1,2,3,4-butanetetraol (Compound C) , (2R,3R)-2,3-0-benzylidene-l,1,4,4-tetra- phenyl-l,2,3,4-butanetetraol (Compound D), (2S,3S)-2,3-0- (1-phenylethylidene)-1,1,4,4-tetrakis(4-methoxyphenyl)- 1,2,3,4-butanetetraol (Compound E) , (2R,3R)-2,3-0~
(1-phenylethylidene)-1,1,4,4-tetrakis(4-methoxyphenyl)- 1,2,3,4-butanetetraol (Compound F) , racemic forms of the above-mentioned compounds, and the like. The compound of general formula (I) and the compound of general formula (II) are used in such a proportion that the amount of compound (II) is 0.1 to 5 equivalents, preferably 0.5 to 2 equivalents, per one equivalent of compound (I). The condensation catalyst is used in an amount of 0.001 to 2 equivalents, preferably 0.01 to 1.2 equivalents, per one equivalent of the compound of general formula (I) . This reaction can sometimes be made to progress more efficiently by adding a dehydrating agent such as Molecular Sieves 4A and the like into the reaction system. Examples of the solvent usable in this reaction include hydrocarbon solvents such as pentane, hexane, heptane, petroleum ether, benzene, toluene, ethylbenzene, trimethylbenzene, triisopropylbenzene and the like; halogenated hydrocarbon solvents such as Flon and the like; ethereal solvents such as ether, tetrahydrofuran and the like; acetonitrile; and mixtures of these solvents. The reaction temperature is recommendably in the range from freezing point of reaction solvent to its boiling point, and preferably in the range of -50°C to about 30°C. For example, by reacting one equivalent of a
2 compound of general formula (I) wherein R is methoxy- carbonyl group, A is' CH2CH2, Y is oxygen and Z is oxygen with 1.25 equivalents of a compound of general formula (II) wherein R 1 is methyl group and *_ is hydrogen atom in the presence of a condensation catalyst
(combination of 0.05 equivalent of dichlorodiisopropoxy- titanium and 0.055 equivalent of (2S,3S)-2,3-0-(l-phenyl- ethylidene)-1,1,4,4-tetraphenyl-l,2,3,4-butanetetraol (Compound A)) and Molecular Sieves 4A, in a solvent mixture consisting of hexane and toluene at a reaction temperature of 0°C, (2S,3S)-3-methoxycarbonyl-l,1-bis- (methylthio)-2-(oxazolidin-2-one-3-yl)-carbonylcyclobutane is obtained in a high chemical yield and a high optical yield. If this reaction is carried out in the presence of a combined catalyst consisting of dichlorodiisopropoxy- titaniu and (2R,3R)-2,3-0-(l-phenylethylidene)-l,1,4,4- tetraphenyl-l,2,3,4-butanetetraol (Compound B) , (2R,3R)- 3-methoxycarbonyl-l,1-bis(methylthio)-2-(oxazolidin-2-one- 3-yl)-carbonylcyclobutane is obtained. Further, if this reaction is carried out by using racemic 2,3-0-(l-phenyl- ethylidene)-1,1, , -tetraphenyl-l,2,3,4-butanetetraol, (±)-(2α,3β)-3-methoxycarbonyl-l,1-bis(methylthio)-2- (oxazolidin-2-one-3-yl)-carbonylcyclobutane is obtained. In the compound of this invention, examples of the alkyl group having 1 to 5 carbon atoms represented by R1, R2 and R3 include alkyl groups such as methyl, ethyl, butyl and the like; examples of the aralkyl group include alkyl groups substituted by an aromatic ring such as benzyl group, 4-methoxybenzyl group and the like; examples of the protected hydroxyalkyl group include benzyloxy- methyl group, acetyloxymethyl group, t-butyldiphenyl- silyloxymethyl group and the like; examples of the protected carboxyl group include alkoxycarbonyl groups such as methoxycarbonyl, ethoxycarbonyl and the like and aralkyloxycarbonyl groups such as benzyloxycarbonyl and the like; examples of the alkoxy group having 1 to 5 carbon atoms include methoxy group, allyloxy group and the like; and examples of the aralkyloxy group include benzyloxy group, 4-methoxybenzyloxy group, t-butyl- diphenylsilyloxy group and the like.
In this invention, examples of the compound represented by general formula (III) include the compounds of general formula (III) wherein R 1, R2, R3, A, Y and Z are as shown in Table 1:
Table
Figure imgf000020_0001
provided that the two R groups in the compound of general formula (III) may be identical or different from each other.
The compounds represented by general formula (V) can be produced, for example, from a compound represented
2 by general formula (III) (herein R is a protected
3 carboxyl group and R is hydrogen atom) according to a process represented by the following Reaction Scheme (5) :
Figure imgf000021_0001
(VII) (VIII)
Figure imgf000021_0002
(IX) (X)
Figure imgf000021_0003
(XI) (V)
Reaction Scheme (5) (in this reaction scheme, R is the same as in general formula (III) , R and R each represents hydrogen atom, alkyl group having 1 to 5 carbon atoms or aralkyl
4 group, R represents hydrogen atom or a protecting group, and X represents an eliminable group).
Thus, in the first step, a compound represented
2 by general formula (III) (herein, R is a protected
3 carboxyl group and R is hydrogen atom) is reacted in an alcoholic solvent such as methanol, ethanol or the like in the presence of a corresponding metallic alkoxide such as magnesium methoxide, sodium ethoxide or the like at a temperature ranging from -78°C to boiling point of the solvent (preferably at a temperature not higher than room temperature) , or solvolyzed in an alcoholic solvent such as methanol, ethanol or the like in the presence of an acid such as hydrochloric acid, p-toluenesulfonic acid and the like or a base such as triethylamine, sodium hydroxide and the like, whereby the corresponding ester represented by general formula (VII) wherein R and R represent hydrogen atom, alkyl group having 1 to 5 carbon atoms or aralkyl group can be obtained. Otherwise, it is hydrolyzed in the presence of an acid such as hydrochloric acid, p-toluensulfonic acid and the like or a base such as sodium hydroxide, potassium carbonate and the like, whereby a carboxylic acid of general formula (VII) wherein R and represent hydrogen atom can be obtained. By reducing the compound of general formula (VII) obtained herein with a metal hydride such as lithium aluminum hydride, di(isobutyl)-aluminum hydride, sodium boron hydride, diborane and the like, an alcohol represented by general formula (VIII) is obtained. Next, the hydroxyl group of the compound of general formula (VIII) is protected to obtain a compound of general formula (IX), and its dithioketal part is hydrolyzed in an aqueous solvent with a halogenating agent such as iodine, N-bromo- succinimide, N-chlorosuccinimide, sulfuryl chloride and the like or a heavy metal compound such as silver nitrate, silver oxide, silver perchlorate, mercury chloride, copper chloride, copper oxide and the like or a combination of these compounds to form a ketone compound represented by general formula (X) .
A compound represented by general formula (X) is reduced with a metal-hydrogen complex compound such as lithium aluminum hydride, lithium tri(t-butoxy)-aluminum hydride, sodium boron hydride, lithium tri(s-butyl)-boron hydride, lithium boron hydride and the like or a metal hydride such as di-isobutyl-aluminum hydride, diborane and the like as a reductant, in a solvent such as hydrocarbon type solvent (e.g. pentane, hexane, heptane, petroleum ether, benzene, toluene, ethylbenzene and the like), halogenated hydrocarbon type solvent (e.g. methylene chloride, chloroform and the like), ethereal solvent (e.g. ether, tetrahydrofuran and the like), alcoholic solvent (e.g. methanol, ethanol and the like), water, or mixture thereof, at a reaction temperature of -100°C to 50°C and preferably -80°C to 30°C, to give a compound represented by general formula (XI). In this reduction, one of the stereoiεomers can be preferentially obtained by selecting the kind of reductant and the conditions of reaction. For example, if 2,3-trans cyclobutanone represented by general formula (Xa) shown in the following Reaction Scheme (6):
Figure imgf000024_0001
(Xa)
Figure imgf000024_0002
(XIa) (Xlb) ti t|
Reaction Scheme (6)
(in this scheme, R represents hydrogen.atom or a protecting group) is reduced with a sterically relatively simple reductant, a 1,2-trans alcohol represented by general formula (Xlb) is selectively formed. However, if the reduction is carried out with a greatly sterically hindered"reductant, a 1,2-cis alcohol represented by general formula (XIa) is preferentially formed. For instance, if (2S,3S)-2,3-bis(t-butyldiphenylsilyloxy- methyl)-l-cyclobutanone is reduced with lithium tri(t- butoxy)-aluminum hydride or sodium boron hydride (both these reductants are not greatly hindered sterically) , (lR,2S,3S)-2,3-bis(t-butyldiphenylsilyloxymethyl)-cyclo- butanol is selectively formed (isolation yield 88% and 80%, respectively). If the same starting compound as above is reduced with lithium tri(s-butyl)-boron hydride or di(isobutyl)-aluminum hydride (both these reductants are greatly hindered sterically), (lS,2S,3S)-2,3-bis(t- butyldiphenylsilyloxymethyl)-cyclobutanol is preferential¬ ly formed (isolation yield 75% and 82%, respectively). The results obtained are as shown in Table 2.
Table 2
Figure imgf000025_0001
* = t-BuPh2Si (in Xa, XIa and Xlb)
The stereoisomers obtained herein, i.e. the compound of general formula (XIa) and the compound of general formula (Xlb), after isolation, are both easily convertible from one to the other. For example, a compound represented by general formula (XIa) or a compound represented by general formula (Xlb) is again oxidized to a ketone represeted by general formula (Xa) by means of conventional oxidant or oxidizing method (for example, metal oxidizing agent such as chromic acid/acetic acid, chromic acid/pyridine and the like, or dimethyl sulfoxide (DMSO)-oxidation method such as DMSO-acetic anhydride/acetic acid, DMSO-oxalyl chloride-triethylamine/ methylene chloride and the like) , after which the oxidized product (Xa) is subjected to a selective reduction. Otherwise, steric configuration of 1-carbon atom to which hydroxyl group is linked in a compound of general formula (XIa) or a compound of general formula (Xlb) is .inverted by utilizing Mitsunobu Reaction, for example. Now, the Mitsunobu Reaction in the latter method will be explained below. Thus a compound represented by general formula (XIa) or (Xlb) is reacted with a trivalent phosphorus compound such as triphenylphosphine, trimethyl phosphite, triethyl phosphite ot the like, a carboxylic acid such as acetic acid, benzoic acid or the like, and an azodicarboxylic ester such as diethyl azodicarboxylate or the like, in a solvent such as hydrocarbon type solvent (e.g. pentane, hexane, heptane, petroleum ether, benzene, toluene, ethylbenzene and the like) , halogenated hydrocarbon solvent (e.g. methylene chloride, chloroform and the like), ethereal solvent (e.g. ether. tetrahydrofuran and the like) or mixture thereof, at a reaction temperature of -100°C to 50°C (preferably -50°C to 30°C) to form an ester. Then, the ester is hydrolyzed with an alkali such as potassium carbonate, sodium hydroxide, sodium methylate, ammonia and the like or an acid such as hydrochloric acid, sulfuric acid and the like or reduced with a metal-hydrogen complex compound such as lithium aluminum hydride, lithium tri(s-butyl)-boron hydride, lithium boron hydride and the like or a metal hydride such as di-isobutyl-aluminurn hydride, diborane and the like. By this treatment, a compound represented by general formula (Xlb) or a compound represented by general formula (XIa) can be obtained. For instance, if (IR,2S,3S)-2,3-bis(t-butyldiphenylsilyloxymethyl)cyclo- butanol is reacted with triphenylphosphme benzoic acid diethyl azodicarboxylate in benzene to form (1S,2S,3S)- l-benzoyl-2,3-bis(t-butyldiphenylsilyloxymethyl)cyclobutane and then the latter is reduced with di-isobutylaluminum hydride in toluene, the benzoyl group can be eliminated, and (lS,2S,3S)-2,3-bis(t-butyldiphenylsilyloxymethyl)- cyclobutanol is obtained. By converting the secondary hydroxyl group of the compound represented by general formula (XI) thus obtained into an leaving group, a compound represented by general formula (V) can be produced.
The experimental examples presented below will demonstrate that the compounds of this invention exhibit wide and strong antiviral and carcinostatic activities. Experimental Example 1
Antiviral activities against simple Herpes 1 type virus (HSV-I) and simple Herpes 2 type virus (HSV-II), both belonging to DNA virus, were examined by the following methods. (Method 1)
A 6-well multi-plate having a single layer of Vero cell (derived from the kidney cell of African Green-Monkey was infected with 100 to 150 PFU (plaque forming units) of virus. After adsorption at 37°C for one hour, a layer of agar medium (Eagle MEM medium containing 1.5% of agar) containing a varied concentration of sample was superposed thereon, and a cultivation was carried out at 37°C for 48 hours in 5% (v/v) carbon dioxide incubator. The formation of plaque was measured, from which 50% inhibitory value (IC_0) was determined.
Experimental Example 2
Antiviral activity against human Cytomegalovirus
(HCMV) belonging to DNA virus was examined by the follow- ing method.
(Method 2)
Anti-HCMV activity was determined in the following manner. Thus, a 35 mm dish having a single layer of human embryonal fibroblast was infected with 100 PFU of HCMV (A0169 strain) . After adsorption for one hour, one layer of a medium (0.5% agarose, 2% fetal calf serum) containing a varied concentration of sample compound was superposed thereon, and cultivation was carried out at 37°C for 10 days in 5% (v/v) carbon dioxide incubator. Then, formation of plaque was measured, from which 50% inhibitory value (IC5Q) was determined.
Experimental Example 3
Antiviral activity against B hepatitis virus (HBV) belonging to DNA virus was examined by the following method. (Method 3) According to the procedure of Dulbecco (Proc.
Natl. Acad. Sci. USA, B - 444 (1987)), cultured liver cell strain HB611 producing and releasing active B hepatitis virus was cultured in a modified Eagle medium (GIBCO) at 37°C at a C02 concentration of 5% in the presence of 10% fetal calf serum, 200 micrograms/ml of G418, 100 μ/ml of Penicillin and 100 μ/ml of Streptomycin. The culture fluid was inoculated onto a 6-well plate at a rate of 5 x 10 cells/well (35 mm). One or two days after, 50% confluence was reached, when a predetermined quantity of sample compound was added and cultivation was continued. Thereafter, cultivation was continued for 15 days, while refreshing the medium with a fresh medium containing the same concentrations of the chemicals at intervals of 3 days. Then, the medium was removed, and the cell bodies were treated with 0.5 ml of Lysis buffer (10 mM Tris HCl, pH 7.8/5 mM Na2EDTA, 1% SDS/0.1 mg/ml Pronase K) at 37βC for one hour and dissolved thereinto. The DNA thus obtained was purified by RNase treatment, phenol- chloroform treatment and ethanol precipitation.
Then, 5 micrograms of DNA was subjected to Hind
III treatment, and DNA pattern was analyzed according to Southern method by using 32P-labelled B hepatitis virus
DNA as a probe.
Experimental Example 4
Antiviral activity against Human Immuno¬ deficiency Virus (HIV) belonging to DNA virus was examined by the following method. (Method 4)
MT-4 cell (about 50,000 cells/ml) was introduced into a 24-well tray, to which was added 100 micrograms of a solution containing a predetermined quantity of sample compound. Culture was carried out at 37°C for 2 hours in 5% (v/v) carbon dioxide incubator. Then, 10 3 to 104
infection units of HIV was added and cultured for 4 days, after which a part of the culture fluid was applied onto a slide glass and immobilized with acetone and development of virus antigen was tested by fluorescent antibody method.
As the primary antibody of fluorescent antibody method, serum of AIDS patient was used. As the secondary antibody, FITC-labelled human IgG was used.
Experimental Example 5 " Carcinostatic activities on human cervical cancer HeLa S- cell, mouse leukemia L1210 cell and human leukemia P388 cell were examined by the following methods (Method 5)
HeLa S3 cell was made into a suspension (7.5 x
3 10 cells/ml) . The suspension was spread on a 96-well flat plate at a rate of 0.2 ml/well. After culturing it at 37°C for 24 hours in 5% carbon dioxide incubator, 10 microliters of a sample was added and cultivation was carried out for 72 hours. Then, culture fluid was taken out from each well and immobilized with methanol, after which 0.1 ml/well of 0.05% Methylene Blue/10 mM-Tris-HCl (pH 8.5) solution was added and dyeing was carried out at room temperature for 30 minutes. The dyed fluid in each well was withdrawn by means of aspirator and three times washed with pure water. Then, 3% HCl was added at a rate of 0.2 ml/well and the resulting mixture was sealed and allowed to stand at room temperature for about 24 hours, to extract pigment from the cells. Optical absorbance of each well at 660 nm was measured by means of Dynatic Microplate Reader, from which growth inhibitory rate (%) at varied concentration was calculated according to the following equation. The results were plotted on a logarithmic probability paper, from which .50% inhibitory concentration (IC5Q, micrograms/ml) was determined.
Growth inhibitory rate (%) = (1 - A1/AQ) x 1 00
wherein A1 = Absorbance in the treated group, A- ■= Absorbance in the control group. (Method 6)
Cells of P388 and L1210 were spread onto a 24-well plate. After adding a sample, it was cultured at 37°C for 48 hours in 5% C02 incubator. After the culture, the number of cells was counted by means of coal tar counter. The growth inhibitory rate in the treated group, based on that in the control group, was calculated from the following equation, from which 50% inhibitory concentration (CI5_, micrograms/ml) was determined: The results obtained are as shown in Table 3.
Growth inhibitory rate (%) = [1-(NT-N0)/ C-N0] x 100
wherein = Cell number in treated group
N_ = cell number at the start of culture N_, = Cell number in control group
Table 3
Figure imgf000032_0001
- 31 -
1 Experimental Example 6
Activity of the sample (compound No. 11) against herpes simplex virus type 2 (HSV-2) infection was examined in mice. Balb/c mice (6 week-old, male) were inoculated
5 intraperitoneally (l.p.) with HSV-2 strain 186 at 4.8 x 10 PFU/0.2 ml per mouse. The sample was formulated in saline and applied either orally (p.o.) or i.p. at the indicated doses once a day for 10 days, starting 6 hrs after virus infection. The mortality was monitored for 20 0 days after inoculation. Efficacy of the sample was indicated as extension of survival time and number of survivors. Aciclovir (ACV: commercialized antivival agent) was used as reference sample.
Results: 5 The results obtained are as shown in Table 4.
Table 4
Figure imgf000034_0001
To evaluate in vivo potential of compound No.
11, it was compared with ACV. Compound No. 11 was highly effective in reducing mortality rate of mice infected with HSV-2 irrespective of administration routes (Table 4). Mean survival time of mice in a control group was 7.7 days, while a number of survivors through an observation period of 20 days was observed in a wide does range of compound No. 11 from 1.25 to 20 mg/kg per day. Survivors were also observed by the treatment of ACV. However, number of the survivors and an effective dose range were much greater with compound No. 11 than with ACV.
Having a strong antiviral activity, the compounds of this invention represented by general formula (IV) are expected to be effectively usable for controlling a number of viral diseases such as herpes labialis, . herpes in the genital organs, herpes zoster, simple infection from Herpesvirus 1 and 2 (HSV-I, II), Varicells zoster virus (VZV) , Cytomegalovirus (CMV) and Epstein-Barr virus (EBV) , viral hapatitis, viral respiratory diseases, viral diseases of the digestive organs, AIDS, ATL, etc.
Further, since they have a carcinostatic activity, they are expectedly usable as a carcinostatic agent.
In using the compounds of this invention obtained in the above-mentioned manner as an antiviral or carcinostatic drug, they can be administered orally, intravenously or percutaneously to the warm-blood animal. Though the dose may vary dependent on symptoms and age of the warm-blood animal and the method of administration. it is usually 0.1 to 500 mg/kg/day. The compounds of this invention are administered in the form of a composition prepared by mixing them with appropriate excipients. As the form of composition, tablet, granule, powder, capsule, injection, cream, suppository, and the like can be used. Next, production of the compounds of this invention will be concretely illustrated by way of the following examples.
Example 1: Production of (-)-(2S,3S)-3-Methoxycarbonyl- 1,1-bis(methylthio)-2-(oxazolidin-2-one-3-yl)- carbonylcyclobutane
Example 1-1
In an atmosphere of argon gas, 80 m of 1,3,5- trimethylbenzene (TMB) was added to dichloroisopropoxy- titanium (905 mg, 3.8 mmol) and (2S,3S)-2,3-0-(1-ph'enyl- ethylidene)-1,1,4,4-tetraphenyl-l,2,3,4-butanetetraol (Compound A) 2.22 g, 4.2 mmol), and the mixture was stirred at room temperature for 30 minutes. Then, powdery Molecular Sieves 4A (3.2 g) was added to the resulting solution and stirred for a while, after which 3-[(E)-3- (methoxycarbonyl)-propenoyl]-oxazolidin-2-one (3.98 g, 20 mmol) was added, and the resulting suspension was cooled to -15°C. Then, 1,1-bis(methylthio)ethylene (3.61 g, 30 mmol) dissolved in 20 ml of TMB solution was slowly added, and temperature of the whole mixture was elevated from that temperature to 0°C over a period of 3 hours with stirring. A saturated aqueous solution of sodium hydrogen carbonate was added to the reaction mixture, the inorganic matter was filtered off with Celite, and the organic matter was extracted with ethyl acetate. The extract solution was washed with saturated aqueous solution of sodium chloride and dried over anhydrous sodium sulfate, and the solvent was distilled off under reduced pressure. The residue was purified by silica gel column chromato¬ graphy (ethyl acetate : hexane = 1 : 2, v/v) to obtain (-)-(2S,3S)-3-methoxycarbonyl-l,l-bis(methylthio)-2- (oxazolidin-2-one-3-yl)-carbonylcyclobutane (3.94 g, 62%). This compound has an optical purity of 86% ee (cf. Example 8) .
NMR (500 MHzFT, CDC1-.) S: 2.01(3H, s),
2.10(3H, s),
2.54(1H, dd, J=9.9, 12.3Hz), 2.70(1H, dd, J=7.9, 12.3Hz), 3.86(1H, dt, Jd=9.9Hz, Jt_-7.9Hz), 3.71(3H, s),
4.02(1H, ddd, J=6.4, 8.9, 11.0Hz), 4.12(1H, ddd, J=7.6, 9.3, 11.0Hz), 4.39-4.47(2H, m), 5.01(1H, d, J=7.9Hz). IR (neat) cm"1: 1780, 1730, 1690.
Example 1-2
In such a manner as in Example 1-1, 3[(E)-3- (methoxycarbonyl)-proρenoyl]-oxazolidin-2-one (3.98 g, 20 mmol), 1,1-bis(methylthio)ethylene (3.61 g, 30 mmol), dichlorodiisopropoxytitanium (474 mg, 2.0 mmol), (2S,3S)-2,3-0-(1-phenylethylidene)-1,1,4,4-tetraphenyl- 1,2,3,4-butanetetraol (Compound A) 1.16 g, 2.2 mmol) and powdery Molecular Sieves 4A (4 g) were reacted in a solvent mixture consisting of toluene (160 ml) and hexane (120 ml) at 0βC for 40 minutes to form (-)-(2S,3S)- 3-methoxycarbonyl-l,1-bis(methylthio)-2-(oxazolidin-2-one- 3-yl)-carbonylcyclobutane (6.13 g, 96%) ([α]D = -10.4° (c 1.34, CH2CI2)). It was recrystallized from methylene chloride-isopropyl ether system to give a compound ([α]D = -11.1° (c 1.15, CH2C12)) in a yield of 5.30 g (83%). Optical purity of this compound was 98% ee or above, as determined by the method mentioned in Example 8.
Example 1-3
In such a manner as in Example 1-1, 3-[(E)-3- (methoxycarbonyl)-propenoyl]-oxazolidin-2-one (19.9 g, 100 mmol), 1,1-bis(methylthio)ethylene (15.03 g, 125 mmol), dichlorodiisopropoxytitanium (1.18 g, 5.0 mmol), (2S,3S)- 2,3-0-(1-phenylethylidene)-1,1,4,4-tetraphenyl-l,2,3,4- butanetetraol (Compound A) (2.91 g, 5.5 mmol) and powdery Molecular Sieves 4A (20 g) were reacted at 0°C for 5 hours in a solvent mixture consisting of toluene (800 ml) and hexane (600 ml) to obtain (-)-(2S,3S)-3-methoxycarbonyl- 1,1-bis(methylthio)-2-(oxazolidin-2-one-3-yl)carbonyl- cyclobutane (26 . 69 g , 84%) ( [α] nD = -10 . 5 ° (c 1 . 00 ,
CH2C12))
Example 2: Production of (+)-(2R,3R)-3-methoxycarbonyl-
1,1-bis(methylthio)-2-(oxazolidin-2-one-3-yl)- carbonylcyclobutane
In an atmosphere of argon gas, dichloroisopro- poxytitanium (125 mg, 0.53 mmol), (2R,3R)-2,3-0- (1-phenylethylidene)-1,1,4,4-tetraphenyl-l,2,3,4- butanetetraol (Compound B) (305 mg, 0.58 mmol) and toluene (5 ml) were mixed together and stirred at room temperature for one hour. A part (0.5 ml, 00.053 mmol) of the resulting solution was taken out and added to powdery Molecular Sieves 4A (100 mg) , and toluene (1.5 ml) was added thereto. To the resulting suspension were added 3-[(E)-3-(methoxycarbonyl)-propenoyl]-oxazolidin-2-one (107 mg, 0.534 mmol) and petroleum ether (boiling point ca. 80°C) (PE) (2 ml), and the resulting mixture was cooled to 0°C. To this suspension, a solution of 1,1-bis(methylthio)-ethylene (115 mg, 0.956 mmol) in PE (1.5 ml) was slowly added, and the resulting mixture was stirred at 0°C for 3 hours. Then, 0.2 M phosphate buffer (pH 7) was added to the reaction mixture and the inorganic matter was filtered off with Celite, after which the organic matter was extracted with ethyl acetate. The extract solution was washed with saturated aqueous solution of sodium chloride and dried over anhydrous sodium sulfate, after which the solvent was distilled off under reduced pressure. The residue was purified by fractionating silica gel thin layer chromatography (ethyl acetate : hexane = 1 : 1, v/v) to give (+)-(2R,3R)-3- methoxycarbonyl-1,1-bis(methylthio)-2-(oxazolidin-2-one- 3-yl)-carbonylcyclobutane (162 mg, 95%). This product had an optical purity of 98% ee (cf. Example 9).
NMR and IR of this product were identical with those of the compound of Example 1.
Example 3: Production of (+)-(2R,3R)-3-Methoxycarbonyl- 1,1-bis(methylthio)-2-(oxazolidin-2-one-3-yl)- carbonylcyclobutane The following table illustrates the results of a study on the conditions in the production of this compound (including Example 2). The other conditions and methods of treatment were the same as in Example 1 or 2.
Figure imgf000040_0001
Figure imgf000040_0002
No. Solvent Catalyst Time Yield Optical purity c)
(eq) (h) (%) (% ee)
Figure imgf000041_0001
a) Oxz is oxazolidin-2-one-3-yl group. b) A mixture (1.0:1.1) of TiCl2(i-PrO)2 and Compound B c) Optical purity was determined from NMR of bis-MTPA ester of Compound (VII). d) TMB means 1,3,5-trimethylbenzene. e) T-PE means toluene-petroleum ether.
Example 4: Production of (+)-l,l-Bis(methylthio)-2-
(oxazolidin-2-one-3-yl)-carbonylcyclobutane The reaction of Example 2 was repeated, except that the 3-[(E)-3-(methoxycarbonyl)propenoyl]-oxazolidin- 2-one was replaced with 3-propenoyl-oxazolidin-2-one, to give (+)-l,l-bis(methylthio)-2-(oxazolidin-2-one-3-yl)- carbonylcyclobutane (82%). This product had an optical purity of 88% ee (cf. Example 10). NMR (500 MHzFT, CDC13) δ: 2.00 (3H, s), 2.12 (3H, s), 2.26-2.33 (IH, m) , 2.34-2.38 ( IH, m) ,
2.39-2 .48 ( IH, m) ,
2 .52-2. 61 (IH, m) ,
4 . 00-4. 13 (2H, m) , 4 .41 (2H, t , J=8. 0Hz) ,
4 . 63 ( lH, . m) .
Example 5: Production of (~)-(2S,3S)-2,3-Bis(methoxy- carbonyl)-!,1-bis(methylthio)-cyclobutane Example 5-1 In an atmosphere of argon gas, lM-dimethoxy- magnesium/methanbl (25 ml, 25 mmol) was added to a methanolic solution (25 ml) of (-)-(2S,3S)-3-methoxy- carbonyl-1,l-bis(methylrhio)-2-(oxazolidin-2-one-3-yl)- carbonylcyclobutane (3.94 g, 12.3 mmol) obtained in Example 1-1 and stirred at room temperature for one hour. The reaction mixture was concentrated under reduced pressure, saturated aqueous solution of ammonium chloride was added to the concentrate, and it was extracted with ether. The ether extract was washed with saturated aqueous solution of sodium chloride, and then the solvent was distilled off under reduced pressure. The residue was purified by silica gel column chromatography (ethyl acetate : hexane = 1 : 9, v/v) to give (-)-(2S,3S)-2,3- bis(methoxycarbonyl)-l,1-bis(methylthio)cyclobutane (2.17 g7 67%). This compound had an optical purity of 86% ee (cf. Example 8) . NMR (500 MHzFT, CDC13) δ:
2.01 (3H, s),
2.12 (3H,. s),
2.47 (IH, dd, J=9.0, 12.2Hz), 2.50 (IH, dd, J=9.4, 12.2Hz),
3.63-3.75 (2H, m),
3.69 (3H, s),
3.72 (3H, s), IR (neat) cm" : 1730.
Example 5-2
In an atmosphere of argon gas, (-)-(2S,3S)-3- methoxycarbony1-1,1-bis(methylthio)-2-(oxazolidin-2-one-3- yl)-carbonylcyclobutane (26.0 g, 81.4 mmol) was added to lM-dimethoxymagnesium/methanol (400 ml, 400 mmol) at 0°C, and the mixture was stirred at that temperature for 15 minutes. Saturated aqueous solution of ammonium chloride was added to the reaction mixture, and it was extracted with ether. After washing the extract solution with saturated aqueous solution of sodium chloride, the solvent was distilled off under reduced pressure. The residue was purified by silica gel column chromatography (ethyl acetate : hexane = 1 : 9, v/v) to give (-)-(2S,3S)-2,3- bis(methoxycarbonyl)-1,1-bis(methylthio)cyclobutane (20.73 g, 96%). Example 6: production of (+)-(2R,3R)-2,3-Bis(methoxy- carbonyl)-1,1-bis(methylthio)-cyclobutane The procedure of Example 5-2 was repeated, except that (+)-(2R,3R)-3-methoxycarbonyl-l,l-bis- (methylthio)-2-(oxazolidin-2-one-3-yl)carbonylcyclobutane produced in Example 2 was used as the starting compound. Thus, (+)-(2R,3R)-2,3-bis(methoxycarbonyl)-l,l-bis- (methylthio)cyclobutane was obtained in a yield of 95%. This compound had an optical purity of 98% ee (cf. Example 9).
NMR and IR of this compound were identical with those of the compound of Example 5.
Example 7: Production of (+)-2-Methoxycarbonyl-l,l-bis- (methylthio)cyclobutane
The procedure of Example 6 was repeated, except that the (+)-l,1-bis(methylthio)-2-(oxazolidin-2-on-- 3-yl)-carbonylcyclobutane produced in Example 4 was used as the starting compound. Thus, (+)-2-methoxycarbonyl- 1,1-bis(methylthio)cyclobutane was obtained in a yield of 83%. This compound had an optical purity of 88% ee (cf. Example 10) .
NMR (500 MHzFT, CDCi δ: 1.97 (3H, S), 2.07 (3H, s),
2.18-2.30 (3H, m), " 2.49 (IH, m), 3.37 (IH, m). 3 . 67 (3H, s) .
Example 8: Production of (-)-(2S,3S)-2,3-Bis(hydroxy- methyl)-1,1-bis(methylthio)cyclobutane In an atmosphere of argon gas, an ethereal solution (10 ml) of (-)-(2S,3S)-2,3-bis(methoxycarbonyl)- 1,1-bis(methylthio)cyclobutane (1.96 g, 7.4 mmol) produced in Example 5-1 was slowly added to an ethereal suspension of lithium aluminum hydride (562 mg, 14.8 mmol) at 0°C, and the resulting mixture was stirred at 0°C for 2 hours. After adding saturated aqueous solution of sodium sulfate to the reaction mixture to decompose the excessive reductant, anhydrous sodium sulfate was added and stirred for a while. Then, the inorganic matter was filtered off and washed with hot isopropyl alcohol. The filtrate and washings were united and the solvent was distilled off therefrom under reduced pressure. The residue was purified by silica gel column chromatography (ethyl acetate : hexane : methanol = 15 : 20 : 1, v/v/v) to obtain (-)-(2S,3S)-2,3-bis(hydroxymethyl)-l,1-bis- (methylthio)cyclobutane (1.48 g, 96%). NMR (270 MHzFT, CDC13) δ:
2.02 (IH, dd, J=9.1, 12.1Hz),
2.05 (3H, s),
2.06 (3H, s), 2.28 (IH, dd, J=8.1, 12.1Hz),
2.47-2.68 (2H, m) , 3.26 (2H, brs). 3 . 54 (IH, dd , J=8 . 8 , 10 .3Hz) ,
3 . 67-3 . 77 (2H, m) , 3 . 83 (IH, dd, J=5 . 0 , 10 .4Hz) , IR(neat) cm" 11 : 3350.
A part of this compound was taken out and converted to bis(R)-TMPA ester in the usual manner by using (R)-α-methoxy-α-trifluoromethyl-phenylacetyl chloride ((R)-MTPACl), dimethylaminopyridine (DMAP)/ pyridine (pyr) . In 500 MHz NMR, four signals of methyl group originated from racemic mixture were observed at 1,852, 1,856, 1,912 and 1,970 ppm. Among them, the methyl group signals at 1,852 and 1,912 ppm were greater than the others, from which optical purity was determined as 86% ee. The title compound (-)-(2S,3S)-2,3-bis-
(hydroxymethyl)-l,l-bis(methylthio)cyclobutane can be made into a crystal having 100% optical purity by recrystal- lization from ethyl acetate-hexane system ([α]D = -32.0° (c 1.03, CH2C12)).
Example 9: Production of (+)-(2R,3R)-2,3-Bis(hydroxy¬ methyl)-1,1-bis(methylthio)-cyclobutane The procedure of Example 8 was repeated, except that (+)-(2R,3R)-2,3-bis(methoxycarbonyl)-1,1-bis- (methylthio)cyclobutane produced in Example 6 was used. Thus, (+)"-(2R,3R)-2,3-bis(hydroxymethyl)-l,l-bis(methyl- thio)cyclobutane was obtained in a yield of 70%. NMR and IR of this compound were identical with those of the compound f Example 8.
A part of this compound was taken out and converted to (R)-TMPA ester according to usual method ((R)-MTPACl, DMAP/pyr) .
NMR of the product was studied according to Example 8. Thus, it was found that the signals of 1,856 and 1,970 ppm were greater than the others, and optical purity was 98% ee. Apart from the above, a part of the title compound was recrystallized from ethyl acetate-hexane system to give a colorless crystal. By X ray analysis of its single crystal, its absolute steric configuration was determined as (2R,3R), as shown in the title.
Example 10: Production of (+)-2-Hydroxymethyl-l,1-bis- methylthio)cyclobutane The procedure of Example 8 was repeated, except that (+)-2-methoxycarbonyl-l,1-bis(methylthio)cyclobutane obtained in Example 7 was used. Thus, (+)-2-hydroxy- methyl-1,1-bis(methylthio)cyclobutane was obtained in a yield of 54%.
NMR (500 MHzFT, CDCl3) δ: 1.92 (IH, m), 2.05 (3H, s), 2.07 (3H, m) ,
2.12-2.32 (4H, m) , 2.68 (IH, m) , 3 . 73 ( IH, dd , J=4 . 8 , 11. 8Hz) ,
3. 84 ( IH, dd, J=7. 5 , 11 . 8Hz) .
A part of this compound was taken out and converted to (R)-MTPA ester according to usual method ((R)-MTPAC1, DMAP/pyr) .
In 500 MHz NMR, four methyl group signals of this compound originated from racemic mixture were found at 1,696, 1,927, 1,930 and 1,955 ppm. Among them, the signals of 1,927 and 1,955 ppm were greater than the others, from which optical purity was determined as 88% ee.
Example 11: Production of (+)-(2S,3S)-2,3-Bis(t-butyl- diphenylsilyloxymethyl)-1,1-bis(methylthio)- cyclobutane Into methylene chloride (25 ml) were dissolved (-)-(2S,3S)-2,3-bis(hydroxymethyl)-l,l-bis(methylthio)- cyclobutane (1.37 g, 6.58 mmol), triethylamine (2.8 ml, 20 mmol),- 4-dimethylaminomethylpyridine catalytic amount) and DMF (1 ml). Then, t-butyldiphenylsilyl chloride (4.52 g, 25 mmol) was added to the solution and stirred at room temperature overnight. After concentrating the reaction mixture under reduced pressure, the concentrate was dissolved into ether, washed with saturated aqueous solution of sodium chloride and dried over anhydrous sodium sulfate. After distilling off the solvent from the etheral solution, the residue was purified by silica gel column chromatography (ether : hexane = 1 : 20, v/v) to give (+)-(2S,3S)-2,3-bis((t-butyldiphenylsilyloxy¬ methyl)-!,l-bis(methylthio)cyclobutane (4.50 g, 100%). NMR (200 MHzFT, CDC13) δ: 0.99 (9H, s), 1.02 (9H, s),
2.06 (6H, s), 2.09-2.25 (2H, m), 2.85 (IH, m), 3.52-3.73 (3H, m), 3.90 (IH, dd, J=9.0, 10.8Hz),
7.26-7.47 (12H, m) , 7.55-7.74 (8H, m),
Example 12: Production of (-)-(2R,3R)-2,3-Bis(t-butyl- diphenylsilyloxymethyl)-l,1-bis(methylthio)- cyclobutane t-Butyldiphenylsilyl chloride (292 mg, 1.06 moles) was added to a solution of (+)-(2R,3R)-2,3-bis- (hydroxymethyl)-l,l-bis(methylthio)cyclobutane (82 mg, 0.39 mmol), imidazole (106 mg,. 1.55 mmol) and 4-dimethylaminomethylpyridine (catalytic amount) in DMF (4 ml), and the resulting mixture was stirred at room temperature overnight. After adding 2M-phosphate buffer (pH 7.0) to the reaction mixture, it was extracted with ethyl acetate. The extract solution was washed with water and then with saturated aqueous solution of sodium chloride and dried over anhydrous sodium sulfate, after which the solvent was distilled off under reduced pressure. The residue was purified by preparing silica gel TLC (ethyl acetate : hexane = 1 : 10, v/v) to give (-)-(2R,3R)-2,3-bis(t-butyldiphenylsilyloxymethyl)-1,1- bis(methylthio)cyclobutane (266 mg, 100%). NMR and IR of this compound were identical with those of the compound of Example 11.
Example 13: Production of (+)-(2S,3S)-2,3-Bis(t-butyl¬ diphenylsilyloxymethyl)-1-cyclobutanone N-Chlorosuccinimide (1.60 g, 12 mmol) and silver nitrate (2.29 g, 13.5 mmol) were dissolved into 80% aqueous solution of acetonitrile (45 ml) , to which was rapidly added at 25°C a solution of (+)-(2S,3S)-2,3-bis- (t-butyldiphenylsilyloxymethyl)-1,1-bis(methylthio)- cyclobutane (2.06 g, 3 mmol) in a mixture consisting of acetonitrile (6 ml) and methylene chloride (1 ml). The resulting mixture was stirred for 10 minutes. After adding 3 ml of saturated aqueous solution of sodium sulfite to the reaction mixture and stirring it for one minute, saturated aqueous solution of sodium hydrogen" carbonate (3 ml) was added and stirred for one minute, and then saturated aqueous solution of sodium chloride (3 ml) was added and stirred for one minute. Then, 60 ml of a mixture of methylene chloride and hexane (1 : 1, v/v) was added to this solution and the insoluble matter was filtered off by the use of Hyflo (S*. (manufactured by
Johns-Manvilie Co.). After drying the filtrate over anhydrous sodium sulfate, the solvent was distilled off under reduced pressure, and the residue was purified by silica gel column chromatography (ether : hexane = 1 : 10, v/v) to obtain (+)-(2S,3S)-2,3-bis(t-butyldiphenyl- silyloxymethyl)-l-cyclobutanone (1.49 g, 82%). NMR (270 MHzFT, CDC13) δ: 1.02 (9H, s),
1.04 (9H, s), 2.74-3.05 (2H, m), 3.29 (IH, m),
3.69 (IH, dd, J=3.7, 10.6Hz), 3.82 (IH, dd, J=4.8, 10.3Hz),
3.88 (IH, dd, J=4.8, 10.3Hz), 3.97 (IH, dd, J=4.0, 10.6Hz), 7.32-7.44 (12H, m) , 7.62-7.68 (8H, m) , IR (neat) cm"1: 1785.
Example 14: Production of (-)-(2R,3R)-2,3-Bis(t-butyl- diphenylsilyloxymethyl)-l-cyclobutanone The procedure of Example 13 was repeated, except that (-)-(2R,3R)-2,3-bis(t-butyldiphenylsilyloxyτnethyl)- 1,1-bis(methylthio)-cyclobutane was used. Thus,
(-)-(2R,3R)-2,3-bis(t-butyldiphenylsilyloxymethyl)-1- cyclobutanone was obtained in a yield of 99%.
NMR and IR of this compound were identical with those of the compound of Example 13. Example 15: Production of 2,3-Bis(t-butyldiphenyl¬ silyloxymethyl)cyclobutanol Example 15-1
In an atmosphere of argon gas, lithium tri(t-butoxy)-aluminum hydride (1.27 g, 5.0 mmol) was added to tetrahydrofuran (THF) (10 ml) and cooled to -78°C. To this suspension was added a solution of (+)-(2S,3S)-2,3-bis(t-butyldiphenylsilyloxymethyl)-1- cyclobutanone (1.21 g, 2.0 mmol) in THF, and temperature of the mixture was slowly elevated to room temperature with stirring over a period of several hours. After adding 0.2 M phosphate buffer to the reaction mixture to decompose the excessive reductant, methylene chloride was added and the inorganic matter was filtered off. The filtrate was extracted with methylene chloride, and the methylene chloride layer was dried over anhydrous sodium sulfate, after which the solvent was distilled off. The residue was separated and purified by silica gel column chromatography (ethyl acetate : hexane = 1 : 9 to 1 : 4, v/v) to obtain (+)-(lS,2S,3S)-2,3-bis(t-butyldiphenyl- silyloxymethyl)cyclobutanol (0.104 g, 9%) : NMR (200 MHzFT, CDC13 δ: 1.00 (9H, S), 1.07 (9H, S), 1.97-2.25 (2H, m) ,
2.32 (IH, m), 2.48 (IH, m). 3.17 (IH, d, J=7.3Hz),
3.56 (2H, d, J=5.8Hz),
3.88 (lH,'dd, J=5.6, 11.4Hz),
3.98 (IH, dd, J=4.0, 11.4Hz), 4.46 (IH, m),
7.26-7.48 (12H, ) ,
7.54-7.72 (8H, m) ,
and (+)-(lR,2S,3S)-2,3-bis(t-butyldiphenylsilyloxymethy1)• cyclobutanol (1.068 g, 88%): NMR (200MHZFT, CDCI S:
1.03 (9H, s),
1.04 (9H, s), 1.60-1.73 (2H, m), 1.92 (IH, m), 2.10-2.37 (2H, m),
3.52-3.70 (3H, m) ,
3.77 (IH, dd, J=4.5, 10.4Hz),
4.03 (IH, m),
7.27-7.46 (12H, m) , 7.56-7.69 (8H, m) .
Example 15-2
In an atmosphere of argon gas, lM-diisobutyl- aluminu hydride/toluene (8.2 ml, 8.2 mmol) was slowly added at -78°C to a solution of (+)-(2S,3S)-2,3-bis(t- butyldiphenylsilyloxymethyl)-l-cyclobutanone (4.12 g, 6.8 mmol) in toluene (70 ml), and the mixture was stirred at that temperature for 10 minutes. After adding 0.2 M phosphate buffer (pH 7) to the reaction mixture and stirring it for a while, an excessive amount of methylene chloride was added and the inorganic matter was filtered off. The filtrate was extracted with methylene chloride and dried over anhydrous sodium sulfate, and then the solvent was distilled off. The residue was purified by silica gel column chromatography {ethyl acetate: hexane = 1 : 9 to 1 : 4, v/v) to give (+)-(lS,2S,3S)-2.3-bis-
(t-butyldiphenylsilyloxymethyl)cyclobutanol (3.38 g, 82%) and (+)-(lR,2S,3S)-2,3-bis(t-butyldiphenylsilyloxymethyl)- cyclobutanol (0.69 g, 17%).
Example 15-3: Transformation from (+)-(lR,2S,3S)-2,3-Bis- (t-butyldiphenylsilyloxymethyl)-cyclobutanol to (+)-(IS,2S,3S)-2,3-Bis(t-butyldiphenyl¬ silyloxymethyl)cyclobutanol Step 1
In an atmosphere of argon gas, diethyl azodicarboxylate (217 microliters, 1.38 mmol) was added to a solution of (+)-(lR,2S,3S)-2,3-bis(t-butyldiphenyl- s'ilyloxymethyl)cyclobutanol (700 mg, 1.15 mmol), benzoic acid (167 mg, 1.37 mmol) and triphenylphosphine (362 mg, 1.38 mmol) in benzene (10 ml), and the resulting mixture was stirred at room temperature overnight. After distilling off volatile substances from the reaction mixture, the residue was purified by silica gel column chromatography (ether : hexane = 1 : 10, v/v) to give (+)-(IS,2S,3S)-l-benzoyl-2,3-bis(t-butyldiphenylsilyloxy¬ methyl)cyclobutane (791 mg, 97%). NMR (200 MHzFT, CDCl.,) δ: 0.97 (9H, s), 1.06 (9H, s), 2.23-2.40 (2H, m), 2.45 (IH, m), 2.85 (IH, m),
3.71 (2H, d, J=5.4Hz), 3.83 (IH, dd, J=6.1, 10.5Hz), 3.99 (IH, dd, J=7.3, 10.5Hz), 5.48 (IH, apparent q, J=6.5Hz), 7.21-7.45 (14H, m),
7.49-7.72 (9H, m) , 7.98 (2H, d, J=7.lHz).
Step 2
In an atmosphere of argon gas, lM-diisobutyl- aluminum hydride/toluene (2.6 ml, 2.6 mmol) was slowly added at -78°C to a solution of (+)-(lS,2S,3S)-l-benzoyl- i ,3-bis(t-butyldiphenylsilyloxymethyl)cyclobutane (790 mg, 1.1 mmol) in toluene (10 ml), and the mixture was stirred at that temperature for 30 minutes. 0.2 M Phosphate buffer (pH 7) was added to the reaction mixture and stirred for a while, after which an excessive amount of methylene chloride was added and the inorganic matter was filtered off. The filtrate was extracted with methylene chloride, the methylene chloride layer was dried over anhydrous sodium sulfate, and the solvent was distilled off therefrom. The residue was separated and purified by silica gel column chromatography (ether : hexane = 1 : 5, v/v) to give (+)-(lS,2S,3S)-2,3-bis(t-butyldiphenyl- silyloxymethyl)cyclobutanol (644 g, 95%).
Example 16: Production of (+)-(lR,2S,3S)-2,3-Bis(t-butyl- diphenylsilyloxymethyl)-l-methanesulfonyloxy- cyclobutane Methanesulfonyl chloride (0.17 ml, 2.2 mmol) was added at 0°C to a solution of (+)-(lR,2S,3S)-2,3-bis- (t-butyldiphenylsilyloxymethyl)cyclobutanol (911 mg, 1.5 mmol) and triethylamine (0.6 ml, 4.3 mmol) in methylene chloride, and the mixture was stirred at 0°C for 15 • minutes. After adding 0.2 M phosphate buffer to the reaction mixture and extracting it with ether, the extract solution was dried over anhydrous sodium sulfate and the solvent was distilled off. The residue was purified by silica gel column chromatography (ethyl acetate : hexane = ϊ : 6, v/v) to give (+)-(lR,2S,3S)-2,3-bis(t-butyl- diphenylsilyloxymethyl)-l-methanesulfonyloxycyclobutane (1.034 g, 100%). NMR (200 MHzFT, CDC13) δ:
1.04 (9H, m),
1.05 (9H, m). 2.07-2.23 (2H, m) ,
2.43 (IH, m),
2.64 (2H, m),
2.91 (3H, m), 3.52-3.65 (3H, m) ,
3.76 (IH, dd, J=4.0, 11.0Hz),
4.97 (IH, m),
7.24-7.48 (12H, m) ,
7.56-7.70 (8H, m) ,
Example 17: Production of (-)-9-[(lS,2R,3S)-2,3-Bis-
(hydroxymethyl)cyclobutane-l-yl]-adenine (Compound 2) Step 1: Production of (+)-9-[(lS,2R,3S)-2,3-bis-
(t-butyldiphenylsilyloxymethyl)cyclobutane-1- yl]-adenine
To a suspension of adenine (177 mg, 1.3 mmol) in DMF (6.5 ml) was added 60% sodium hydride (52 mg, 1.3 mmol). After stirring the mixture for one hour, a solution of (+)-(lR,2S,3S)-2,3-bis(t-butyldiphenyl- silyloxymethyl)-l-methanesulfonyloxycyclobutane (450 mg, 0.65 mmol) in DMF (1.5 ml) was added to the reaction mixture and stirred at 145°C for 6 hours. After cooling, 0.2 M phosphate buffer was added and the mixture was extracted with ethyl acetate. The extract solution was dried over anhydrous sodium sulfate, and then the solvent was dried over anhydrous sodium sulfate, and then the solvent was distilled off. The residue was separated and purified by silica gel column chromatography (methylene chloride : methanol = 50 : 1 to 30 : 1, v/v) to give unreacted (+)-(lR,2S,3S)-2,3-bis(t-butyldiphenylsilyloxy- methyl)-l-methanesulfonyloxycyclobutane (100 g, 22% recovery) and (+)-9-[(lS,2R,3S)-2,3-bis(t-butyldiphenyl- silyloxymethyl)cyclobutane-l-yl]-adenine (203 mg, 43%). NMR (400 MHzFT, CD3OD) S: 0.75 (9H, s), 1.03 (9H, s), 2.42-2.54 (2H, m) ,
2.92-3.08 (2H, m) , 3.53 (IH, dd, J=4.0, 11.0Hz), 3.68 (IH, dd, J=8.8, 11.0Hz), 3.73-3.85 (2H, m) , 5.23 (IH, m),
7.20-7.46 (16H, m) , 7.60-7.72 (4H, m), 8.18 (IH, s).
Step 2: Production of (-)-9-[(lS,2R,3S)-2,3-bis(hydroxy- methyl)cyclobutane-l-yl]-adenine (Compound 2)
To a methanolic solution (1 ml) .of (+)-9- [(IS,2R,3S)-2,3-bis(t-butyldiphenylsilyloxymethyl)- cyclobutane-1-yl]-adenine (203 mg, 0.28 mmol) obtained in Step 1 was added 4N-hydrochloric acid/dioxane (0.15 ml, 0.6 mmol). After stirring the mixture at room tempera¬ ture overnight, the solvent was distilled off from the reaction mixture under reduced pressure, and water was added. After removing ether-soluble substances, it was neutralized with 0.1 N sodium hydroxide solution and the solvent was distilled off. The crude product thus obtained was purified by Sephadex LH-20 column chromato- graphy (methanol : water = 1 : 1, v/v) and then washed with acetone to give (-)-9-[(lS,2S,3S)-2,3-bis(hydroxy- methyl)cyclobutane-l-yl]-adenine (Compound 2) (26 mg, 37%). NMR (400 MHzFT, CD3OD) δ: 2.43-2.57 (2H, m) , 2.78 (IH, m) ,
3.03 (IH, m),
3.41 (IH, dd, J=6.2, 11.4Hz), 3.46 (IH, dd, J=7.3, 11.4Hz), 3.74 (2H, d, J=6.2Hz), 5.25 (IH, apparent q, J=8.1Hz),
8.20 (IH, S), 8.37 (IH, S). UV λmax (H20) nm: pH 1,258; pH 7,260; pH 13,260.
Example 18: Production of (-)-9-[(lS,2R,3S)-2,3-Bis-
(hydroxymethyl)cyclobutane-1-yl]-guanine (Compound 5) Step 1: Production of (-)-2-amino-9-[(lS,2R,3S)-2,3-bis- (t-butyldiphenylsilyloxymethyl)cyclobutane-1- y1]-6-(2-methoxyethoxy)-purine Lithium hydride (10 mg, 1.3 mmol) was added to a suspension of 2-amino-6-(2-methoxyethoxy)-purine (274 mg, 1.3 mmol) in DMF (6.5 ml), and the mixture was stirred for one hour. Then, a solution of (+)-(lR,2S,3S)-2,3- bis(t-butyldiphenylsilyloxymethyl)-1-methanesulfonyloxy- cyclobutane (450 mg, 0.65 mmol) in DMF (1.5 ml) was added to the reaction mixture, and stirred at 145°C for 6 hours. After cooling, 0.2 M phosphate "buffer and ethyl acetate were added, the insoluble matter was filtered off, and then the filtrate was extracted with ethyl acetate. The extract solution was dried over anhydrous sodium sulfate, and the solvent was distilled off. The residue was purified by silica gel column chromatography (ethyl acetate : hexane = 5 : 1 to 3 : 1, v/v) to give unreacted (+)-(lR,2S,3S)-2,3-bis(t-butyldiphenylsilyloxymethyl)- 1-methanesulfonyloxycyclobutane (157 mg, 35% recovery) and (-)-2-amino-9-[(IS,2R,3S)-2,3-bis(t-butyldiphenyl¬ silyloxymethyl)cyclobutane-l-yl]-6-(2-methoxyethoxy)- purine (160 mg, 31%).
NMR (400 MHzFT, CI>3OD) δ: 0.79 (9H, s), 1.03 (9H, s),
2.38-2.40 (2H, m) , 2.92 (IH, m) , 2.98 (IH, m),
3.54 (IH, dd, J=4.0, 11.0Hz),
3.68 (lH, dd, J=8.8, 11.0Hz),
3.72-3.85 (4H, m) , 4.56-4.67 (2H, m) ,
5.18 (IH, apparent q, J=8.0Hz),
7.23-7.47 (16H, m) ,
7.50-7.60 (4H, m) ,
8.07 (IH, s).
Step 2: Production of (-)-9-[(lS,2R,3S)-2,3-bis(hydroxy- methyl)cyclobutane-l-yl]-guanine (Compound 5) 2 N hydrochloric acid (1 ml) was added to (-)-2-amino-9-[(IS,2R,3S)-2,3-bis(t-butyldiphenyIsilyloxy- methyl)cyclobutane-l-yl]-6-(2-methoxyethoxy)-purine (140 mg, 0.17 mmol) obtained in Step 1, and the mixture was heated under reflux for one hour. After distilling off the solvent from the reaction mixture under reduced pressure, water was added and the ether-soluble substances were removed. Then, it was neutralized with 0.1 N sodium hydroxide solution and the solvent was distilled off. The residue was purified by HP-20 column chromatography (water : methanol = 1 : 0 to 1 : 3, v/v) and then washed with acetone to give (-)-9-[(lS,2R,3S)-2,3-bis(hydroxy- methyl)cyclobutane-l-yl]-guanine (Compound 5) (15 mg, 32%). NMR (400 MHzFT, CD3OD) δ: 2.36-2.55 (2H, m), 2.72 (IH, ), 2.90 (IH, m),
3.45 (2H, d, J=7.0Hz), 3.70 (2H, d, J=6.2Hz),
5.05 (IH, apparent q, J=8.1Hz), 7.94 (IH, s),
UV λmax (H20) nm: pH l,253,279(sh); pH 7,252,272(sh); pH I3,257(sh), 267.
Example 19: Production of (+)-(lS,2S,3S)-2,3-Bis(t-butyl- diphenylsilyloxymethyl)-l-methanesulfonyloxy- cyclobutane The treatment of Example 16 was repeated, except that (+)-(IS,2S,3S)-2,3-bis(t-butyldiphenylsilyloxy¬ methyl)cyclobutanol was used. Thus, (+)-(lS,2S,.3S)-2,3- bis(t-butyldiphenylsilyloxymethyl)-methanesulfonyloxy- cyclobutane was obtained in a quantitative yield. NMR (200 MHzFT, CDC13) δ: .1.04 (9H, s),
1.06 (9H, S), .2.25-2.53 (3H, m),
2.78 (IH, m),
2.87 (3H, s),
3.65 (2H, d, J=4.0Hz),
3.85 (IH, dd, J=6.3, 10.5Hz), 3.93 (IH, dd, J=6.5, 10.5Hz),
• 5.25 (IH, m),
7.32-7.50 (12H, m), 7. 60-7. 75 ( 8H, m) .
By recrystallizing this compound from ether- hexane system, a crystalline product (Cα]D = +12.0° (c 1.01, CH2C12)) (optical purity 100%) could be obtained.
Example 20: Production of (-)-9-[(lR,2R,3S)-2,3-Bis-
(hydroxymethyl)cyclobutane-l-yl]-adenine (Compound 8) Step 1: Production of (+)-9-[(lR,2R,3S)-2,3-bis(t- butyIdiphenylsilyloxymethyl)cyclobutane-1-yl]- adenine
To a suspension of adenine (100 mg, 0.74 mmol) in DMF (4 ml) was added 60% sodium hydride (30 mg, 0.75 mmol). After stirring the mixture for one hour, a solution of (+)-(lS,2S,3S)-2,3-bis(t-butyldiphenyl- silyloxymethyl)-1-methanesulfonyloxycyclobutane (254 mg, 0.37 mmol) in DMF (1.5 ml) was added to the reaction mixture and stirred at 145°C for 6 hours. After cooling, 0.2 M phosphate buffer was added and the mixture was extracted with ethyl acetate. The extract solution was dried over anhydrous sodium sulfate and the solvent was distilled off. The residue was purified by silica gel column chromatography (methylene chloride : methanol = 30 : 1, v/v) to give (+)-9-[(lR,2R,3S)-2,3-bis(t-butyl- diphenylsilyloxymethyl)cyclobutane-l-yl]-adenine (126 mg, 47%). - 62 -
NMR (200 MHzFT, CDC13) δ 0.98 (9H, s),
1.06 (9H, s), 2.30-2.65 (3H, m) ,
3.07 (IH, m), 3.62-3.84 (4H, m) , 4.81 (IH, m), 5.61 (2H, brs), 7.20-7.52 (12H, m) , 7.52-7.75 (8H, m) , 7.85 (IH, s),
8.33 (IH, s).
Step 2: Production of (-)-9-[(lR,2R,3S)-2,3-bis(hydroxy- methyl)cyclobutane-l-yl]-adenine (Compound 8) To methanolic solution (2 ml) of (+)-9-
[(1R,2R,3S)-2,3-bis(t-butyldiphenylsilyloxymethyl)- cyclobutane-l-yl]-adenine (118 mg, 0.16 mmol) obtained in Step 1 was added 4 N-hydrochloric acid/dioxane (0.17 ml, 0.65 mmol), and the mixture was stirred at room temperature overnight. After distilling off the solvent from the reaction mixture under reduced pressure, water was added and ether-soluble substances were removed. Then, it was neutralized with 0.1 N aqueous solution of sodium hydroxide and the solvent was distilled off. The crude product thus obtained was purified by Sephadex HP-20 column chromatography (water : methanol = 1 : 0 to 1 : 1, v/v), and thereafter by silica gel column chromatography (methylene chloride : ethanol = 5 : 1, v/v) and further thereafter by Sephadex LH-20 column chromatograhy (methanol) to give (-)-9-[(lR,2R,3S)-2,3-bis(hydroxy- methyl)cyclobutane-l-yl]-adenine (Compound 8) (37 mg, 91%). NMR (200 MHzFT, CD3OD) δ: 2.24 (IH, m),
2.37 (IH, apparent q, J=9.5Hz), 2.62 (IH, m), 2.88 (IH, m), 3.65-3.74 (4H, m) ,
4.71 (IH, apparent q, J=8.5Hz), 8.20 (IH, s), 8.26 (IH, s), UV λmax (H20) nm: pH 1,259; pH 7,259; pH 13,259.
HRMS (FAB)
Calcd for [C1]H15 502+H]+; 250, 1304 Found: 250, 1305.
By recrystallizing this compound from ether- methanol system, a crystalline product (Cα D = -44.7° (c 0.98, pyridine) (optical purity: 98% or above) was obtained.
By repeating the procedure of this example with the corresponding bases. Compounds No. 26, No. 29, No. 32 and No. 35 were also obtained. The physicochemical properties of No. 26 and No. 32 are shown as follows: 6
NMR (200 MHzFT, CD3OD) δ: 2.30-2.46 (2H, m) , 2.38 (IH, m), 2.57 (IH, m), 3.51-3.71.(4H, m) , 4.54 (IH, m), 5.69 (IH, d, J=8.0Hz), 7.80 (IH, d, J=8.0Hz), UV λmax (H20) nm: ρHl,268; pH7,268; pHl3,267.
2
NMR (200 MHzFT, CD3OD) δ: 1.78-2.14 (2K, m), 2.20-2.54 (2H, m), 3.50-3.76 (4H, m), 4.50 (IH, m), 5.91 (IH, d, J=7.4Hz), 7.78 (IH, d, J=7.4Hz),
UV λmax (H20) rim: pHl,284; pH7,273; pH13,274. _. Example 21: Production of (+)-9-[(lR,2R,3S)-Bis(hydroxy- methyl)cyclobutane-l-yl]-guanine (Compound 11) Step 1: Production of (+)-2-amino-9-[(lR,2R,3S)-2,3-bis- (t-butyldiphenylsilyloxymethyl)cyclobutane-1- 5 yl]-6-(2-methoxyethoxy)-purine
Lithium hydride (6 mg, 0.75 mmol) was added to a suspension of 2-amino-6-(2-methoxyethoxy)-purine (155 mg, 0.74 mmol) in DMF (4 ml), and the mixture was stirred for one hour. Then, a solution of (+)-(lS,2S,3S)-2,3-bis- (t-butyldiphenylsilyloxymethyl)-l-methanesulfonyloxy- cyclobutane (450 mg, 0.65 mmol) in DMF (1.5 ml) was added to the reaction mixture and stirred at 145°C for 6 hours. After cooling, 0,2 M phosphate buffer and ethyl acetate were added and the insoluble matter was filtered off, and the filtrate was extracted with ethyl acetate. After drying the extract solution over anhydrous sodium sulfate, the solvent was distilled off. The residue was purified by silica gel column chromatography (methylene chloride : ethyl acetate = 10 : 1, v/v) to give (+)-2-amino-9- [(lR,2R,3S)-2,3-bis(t-butyldiphenylsilyloxymethyl)- cyclobutane-l-yl]-6-(2-methoxyethoxy)-purine (88 mg, 30%). NMR (200 MHzFT, CDC1.-) δ 1.01 (9H, s), 1.05 (9H, s), 2.25-2.60 (3H, m) ,
2.92 (IH, m), 3.44 (3H, s), 3.60-3.94 (6H, m) , 4 . 50-4 . 90 (5H, m) ,
7 . 15-7. 55 ( 12H, m) , 7.55-7. 80 ( 8H, m) , 7. 67 ( IH, s) .
When DMSO and HMPA were used as the solvent of this reaction, the reaction progressed at 75°C and 100°C, respectively, to give results similar to the results in case of DMF.
Step 2: Production of (+)-9-[(lR,2R,3S)-2,3-bis(hydrozy- methyl)cyclobutane-1-yl]-guanine (Compound 11)
To methanolic solution (2 ml) of (+)-amino-9- [(IR,2R,3S)-2,3-bis(t-butyldiphenylsilyloxymethyl)- cyclobutane-l-yl]-6-(2-methoxyethoxy)-purine (79 mg, 0.10 mmol) obtained in Step 1 was added 4N-hydrochloric acid/dioxane (0.1 ml, 0.4 mmol). After stirring the mixture overnight at room temperature, the solvent was distilled off from the reaction mixture under reduced pressure. Then, water was added, ether-soluble substances were removed, the solvent was distilled off, 2 N-hydro- chloric acid (2 ml) was added, and the mixture was heated under reflux for one hour. After neutralizing the reaction mixture with 1 M aqueous solution of sodium hydroxide, it was purified by Sephadex HP-20 column chromatography (water : methanol = 1 : 0 to 1 : 4, v/v) to give (+)-9-[(lR,2R,3S)-2,3-bis(hydroxymethyl)- cyclobutane-1-yl]-guanine (Compound 11) (23 mg, 88%). - 67 - NMR (200 MHzFT, CD3OD) δ: 2.18 (IH, m) ,
2.32 (IH, apparent q, J=10.0Hz), 2.50 (IH, m), 2.79 (IH, m),
3.62-3.74 (4H, m) , 4.54 (IH, apparent q, J-=8.8Hz), 7.89 (IH, s), UV λmax (H_0) n : pH l,253,277(sh); pH 7,253,268(sh) ; pH 13,256(sh) , 267. HRMS (FAB)
Calcd for [CnH15 503+H]+; 266, 1253 Found: 266, 1251.
By recrystallizing this compound from water, a crystalline product ([α]D = +26.5° (c 0.99, O.lN-NaOH) (optical purity: 98% or above) could be obtained.
By repeating the procedure of this example with the corresponding bases, compounds. No. 14, No. 17, No. 20 and No. 23 were obtained similarly.
Example 22: Production of (lR,2R,3S)-l-Amino-2,3-bis-
(t-butyldiphenylsilyloxymethyl)cyclobutane Step 1: Production of (lR,2R,3S)-l-azido-2,3-bis(t- butyldiphenylsilyloxymethyl)cyclobutane In an atmosphere of argon gas, sodium azide (975 mg, 15 mmol) was added to a solution of (+)-(lS,2S,3S)- 2,3-bis(t-butyldiphenylsilyloxymethyl)-l-methane- sulfonyloxycyclobutane (1.03 g, 1.5 mmol) in DMF (6 ml), and the mixture was stirred at 120°C for 2 hours. After cooling, the reaction mixture was diluted with water and extracted with ether, and the ether extract solution was washed twice with water and then with saturated aqueous solution of sodium chloride. After drying the ethereal solution over anhydrous sodium sulfate, the solvent was distilled off under reduced pressure and the residue was purified by silica gel column chromatography (methylene chloride : hexane = 1 : 4, v/v) to give (1R,2R,3S)- l-azido-2,3-bis(t-butyldiphenylsilyloxymethyl)cyclo¬ butane (992 mg, quantitative yield). IR (neat) cm" : 2100. NMR (200 MHzFT, CDC13) δ: 1.03 (9H, s),
1.05 (9H, s), 1.91 (IH, m), 2.02-2.29 (2H, m) , 2.44 (IH, m), 3.51-3.65 (4H, m),
3.71 (IH, dd, J=4.0Hz, 10.8Hz), 7.31-7.44 (12H, m), 7.57-7.67 (8H, m) .
Step 2: Production of (lR,2R,3S)-l-amino-2,3-bis(t-butyl- diphenylsilyloxymethyl)cyclobutane
The (lR,2R,3S)-l-azido-2,3-bis(t-butyldiphenyl- silyloxymethyl)cyclobutane (992 mg) produced in Step 1 was dissolved into ethyl acetate (2 ml) . After adding 10% palladium-carbon (100 mg), the solution was stirred in an atmosphere of hydrogen at room temperature overnight. After filtering off the catalyst, the solvent was distilled off under reduced pressure, and the residue was purified by silica gel column chromatography (hexane : ethyl acetate : triethylamine = 20 : 10 : 1, v/v/v) to give (lR,2R,3S)-l-amino-2,3-bis(t-butyldiphenylsilyloxy¬ methyl)cyclobutane (642 mg, 67%). NMR (200 MHzFT, CDC13) δ: 1.03 (9H, S), 1.05 (9H, S), 1.42 (IH, m),
1.54 (2H, brs, exchangeable with D20), 1.86-2.05 (2H, m) ,
2.24 (IH, m), 3.13 (IH, m), 3.54-3.65 (3H, m) , 3.75 (IH, dd, H=4.1, 10.6Hz), 7.27-7.46 (12H, m) ,
7.58-7.69 (8H, m) .
Example 23: Production of l-[(lR,2R,3S)-2,3-Bis(hydroxy- methyl)cyclobutane-1-yl]-5-methyl-2,4(IH,3H)- pyrimidindione (Compound 29) Step 1: Production of N-[[(1R,2R,3S)-2,3-bis(t-butyl¬ diphenylsilyloxymethyl)cyclobutyl]amino- carbonyl]-3-methoxy-2-methylacrylamide In an atmosphere of argon gas, a suspension of 3-methoxy-2-methylacrylic acid chloride (673 mg, 5 mmol) and silver cyanate .(1.50 g, 10 mmol) in anhydrous benzene (10 ml) was heated under reflux for one hour, and then allowed to stand at room temperature. Supernatant (2.6 ml) of this mixture was taken out and added at 0°C to a solution of (lR,2R,3S)-l-amino-2,3-bis(t-butyldiphenyl¬ silyloxymethyl)cyclobutane (603 mg, 0.99 mmol) in anhydrous benzene (4 ml), and the resulting mixture was stirred overnight as it was. Then, the solvent was distilled off from the reaction mixture under reduced pressure, and the residue was purified by silica gel column chromatography (hexane : ether = 1 : 1, v/v) to give crude N-[[(lR,2R,3S)-2,3-bis(t-butyldiphenyl- silyloxymethyl)cyclobutyl]aminocarbonyl]-3-methoxy-2- methylacrylamide (592 mg) .
Step 2: Production of l-[(lR,2R,3S)-2,3-bis(hydroxy- methyl)cyclobutan-1-yl]-5-methyl-2,4(IH,3H)- pyrimidindione (Compound 29) lM-Tetrabutylammonium fluoride/THF (2.4 ml, 2.4 mmol) was added to a solution of the N-[[(1R,2R,3S)- 2,3-bis(t-butyldiphenylsilyloxymethyl)cyclobutyl]amino¬ carbonyl]-3-methoxy-2-methylacrylamide (590 mg) obtained in Step 1 in methanol (8 ml), and the mixture was stirred overnight at room temperature. After distilling off the solvent from the reaction mixture, water and ether were added and it was extracted with water six times. The water extracts were concentrated under reduced pressure, 1M sulfuric acid (10 ml) was added thereto, and the mixture was heated under reflux for 30 minutes. The reaction mixture was neutralized with sodium hydroxide solution and purified with Sephadex HP-20 (water-30% aqueous methanol) and thereafter with Dowex 50w-X8 (H-form, water) . After neutralizing the eluate with sodium hydroxide solution, it was again purified with Sephadex HP-20 (water-30% aqueous methanol) to give 1-[(IR,2R,3S)-2,3-bis(hydroxymethyl)cyclobutane-l-yl]-5- methyl-2, -(1H,3H)-pyrimidindione (compound 29) (127 mg, 67%).
NMR (200 MHzFt, CD3OD) δ:
1.90 (3H, d, J=l.lHz), 1.97-2.18 (2H, ), 2.36 (IH, m),
2.58 (IH, m), 3.57-3.70 (4H, m), 4.55 (IH, m), 7.63 (IH, d, J=l.lHz), UV λmax (H20) nm: pH 1,273; pH 7,273; pH 13,271. Example 24: Production of 2-Amino-9-[(lR,2R,3S)-2,3-bis-
(hydroxymethyl)cyclobutane-l-yl]-6-chloro- purine (Compound 17) Step 1: production of 2-amino-9-[(lR,2R,3S)-2,3-bis- (acetoxy ethyl)cyclobutane-l-yl]-6-chloropurine
Pyridine (0.5 ml) and acetic anhydride (1 ml) were added to a suspension of 9-[(lR,2R,3S)-2,3-bis- (hydroxymethyl)cyclobutane-l-yl]-guanine (Compound 11) (265 mg, 1.0 mmol) in anhydrous dimethylformamide (1.5 ml), and the mixture was stirred at 75°C for 30 minutes. After distilling off the solvent under reduced pressure, the residual solvent was eliminated by azotropically distilling it together with toluene several times, after which the residue was dried. Thus, crude 9-[(lR,2R,3S)- 2,3-bis(acetoxymethyl)cyclobutane-l-yll-guanine- (350 mg) was obtained.
The crude 9-[(lR,2R,3S)-2,3-bis(acetoxymethyl)- cyclobutane-l-yl]-guanine (350 mg) thus obtained was dissolved into anhydrous acetonitrile (2 ml) together with tetraethylammonium chloride (331 mg, 2.0 mmol), to which were added N,N-dimethylaniline (130 microliters, 1.0 mmol) and phosphorus oxychloride (0.57 ml, 6.0 mmol). The mixture was heated under reflux at 100°C for 10 minutes. After distilling off volatile substances from the reaction mixture under reduced pressure, crushed ice and methylene chloride were added to the residue and stirred at 0CC for a while, and then it was neutralized with saturated aqueous solution of sodium hydrogen carbonate. After stirring the mixture at 0°C for a while, it was extracted with methylene chloride. The methylene chloride extract solution was dried over anhydrous sodium sulfate, and then the solvent was distilled off. The residue was purified by silica gel column chromatography (methylene chloride : ethyl acetate = 1 : 1, v/v) to give 2-amino-9-[(IR,2R,3S)-2,3-bis(acetoxymethyl)- cyclobutane-l-yl]-6-chloropurine (335 mg, 91%). NMR (200 MHzFT, CDCI δ: 2.02 (3H, S),
2.11 (3H, S), 2.18-2.73 (3H, m), 3.09 (IH, m), 4.25 (4H, d, J=5.9Hz), 4.59 (IH, apparent q, J=8.4Hz),
4.65 (2H, br), 7.88 (IH, s).
Step 2: Production of 2-amino-9-[(lR,2R,3S)-2,3-bis-
(hydroxymethyl)cyclobutane-l-yl]-6-chloropurine (Compound 17)
2-Amino-9-[(I ,2 ,3S)-2,3-bis(acetoxymethyl)- cyclobutane-l-yl]-6-chloropurine (98 mg, 0.27 mmol) was dissolved into methanol (2 ml), mixed with potassium carbonate (90 mg, 0.65 mmol) and stirred at 0°C for 30 minutes. The reaction mixture was neutralized with
IN-hydrochloric acid and then purified with Sephadex HP-20 (water-60% aqueous methanol) to give 2-amino-9- [(1R,2R,3S)-2,3-bis(hydroxymethyl)cyclobutane-1-yl]-6- chloropurine (Compound 17) (65 mg, 86%) . NMR (200 MHzFT, CD OD) δ: 2.20 (IH, m), 2.37 (IH, m),
2.57 (IH, m), 2.89 (IH, m), 3.69 (4H, d, J=5.5Hz), 4.64 (IH, apparent q, J=8.8Hz), 8.19 (IH, s).
UV λmax (H20) nm: pH l,244(sh), 313; pH 7,248(sh), 3.6; pH 13,248(sh), 305.
Example 25: Production of 2-Amino-9-[(lR,2R,3S)-2,3-bis- (hydroxymethyl)cyclobutan-1-yl]-purine
(Compound 14) Step 1: Production of 2-amino-9-[(lR,2R,3S)-2,3-bis- (acetoxymethyl)cyclobutane-l-yl]-purine 2-Amino-9-[(IR,2R,3S)-2,3-bis(acetoxymethyl)- cyclobutane-l-yl]-6-chloropurine (87 mg, 0.24 mmol) was dissolved into methanol (2 ml) . After adding 10% palladium carbon (13 mg) , it was stirred overnight at room temperature in an atmosphere of hydrogen gas. After adding a small amount of saturated aqueous solution of potassium hydrogen carbonate to the reaction mixture and filtering off the catalyst, the solvent was distilled off under reduced pressure and the residue was purified by silica gel column chromatography (methylene chloride : methanol = 20 : 1, v/y) to give 2-amino-9-[(1R,2R,3S)- 2,3-bis(acetoxymethyl)cyclobutane-l-yl]-purine (56 mg, 71%). NMR (200 MHzFT, CDC13) δ: 2.01 (3H, s), 2.12 (3H, s), 2.28-2.71 (3H, m), 3.11 (IH, m), 4.17-4.34 (4H, m) ,
4.60 (IH, apparent q. J=8.6Hz), 5.11 (2H, brs), 7.80 (IH, s), 8.70 (IH, s).
Step 2: Production of 2-amino-9-[(lR,2R,3S)-2,3-bis-
(hydroxymethyl)cyclobutane-l-yl]-purine (Compound 14) 2-Amino-9-[(IR,2R,3S)-2,3-bis(acetoxymethyl)- cyclobutane-l-yl]-chloropurine (40 mg, 0.12 mmol) was dissolved into methanol (2 ml), mixed with potassium carbonate (40 mg, 0.29 mmol) and stirred at 0°C for 30 minutes. After neutralizing the reaction mixture with 0.1 N hydrochloric acid, it was purified with Sephadex HP-20 (water-50% aqueous methanol) to give 2-amino-9- [(IR,2R,3S)-2,3-bis(hydroxymethyl)cyclobutane-1-yl]- purine (Compound 14) (27 mg, 90%). NMR (200 MHzFT, CDgOD) δ:
2.10-2.66 (3H, m) ,
2.90 (IH, m),
3.70 (4H, d, J=5.6Hz), 4.65 (IH, apparent q, J=8.7Hz),
8.20 (IH, s),
8.54 (IH, s). UV λmax (H20) nm: pH l,252(sh), 312; pH 7,244(sh), 304; pH 13,244(sh), 304.
Example 26: Production of 2,6-Diamino-9-[(lR,2R,3S)- 2,3-bis(hydroxymethyl)cyclobutane-l-yl]- purine (Compound 20) 2-Amino-9-[(IR,2R,3S)-2,3-bis(acetoxymethyl)- cyclobutane-l-yl]-chloropurine (87 mg, 0.24 mmol) was dissolved into methanol (2 ml) and cooled to -78°C. The solution thus obtained was saturated with liquid ammonia, sealed into an ampoule and heated at 100°C for 12 hours. After distilling off volatile substances from the reaction mixture under reduced pressure, it was dissolved into water, neutralized with 0.1 N sodium hydroxide solution and purified with Sephadex HP-20 (water-40% aqueous methanol) to give 2,6-diamino-9-[(lR,2R,3S)-2f3-bis- (hydroxymethyl)cyclobutane-l-yl]-purine (Compound 20) (41 mg, 82%).
NMR (200 MHzFT, CD3OD) δ: 2.19 (IH, m). 2.31 (IH, m),
2.54 (IH, m), 2.75 (IH, m), 3.61-3.74 (4H, m) , 4.49 (IH, apparent q, J=8.6Hz),
7.90 (IH, s). UV λmax (H20) nm: pH 1,253,291; pH 7,255,280; pH 13,255,280.
Example 27: Production of 9-[(lR,2R,3S)-2,3-Bis(hydroxy- methyl)cyclobutane-1-yl]-hypoxanthine
(Compound 23) 9-[(IR,2R,3S)-2,3-Bis(hydroxymethyl)-cyclo- butane-1-yl]-adenine (Compound 8) (25 mg, 0.10 mmol) was dissolved into water (2.5 ml), mixed with sodium nitrate (138 mg, 2.0 mmol) and cooled to 0°C. After adding acetic acid (0.13 ml), the mixture was stirred at room temperature for one day. The reaction mixture was neutralized with 1 N sodium hydroxide solution and then purified with Sephadex HP-20 (water-40% aqueous methanol) to give 9-[(lR,2R,3S)-2,3-bis(hydroxymethyl)cyclobutane- 1-yl]-hypoxanthine (Compound 23) (23 mg, 90%). NMR (200 MHzFT, CD3OD) δ: 2.25 (IH, m), 2.38 (IH, m), 2.58 (IH, m),
2.90 (IH, m), 3.66-3.74 (4H, m) , 4.76 (IH, apparent q, J=8.5Hz),
8.04 (IH, s), 8.20 (IH, s). UV λmax (H20) nm: pH 1,250; pH 7,250; pH 13,254.
INDUSTRIAL APPLICABILITY:
Cyclobutane derivatives of this invention are useful as medical drugs as antiviral agent, carcinostatic agent, a d the like.

Claims

CLAIMS :
1. A cyclobutane derivative represented by the following general formula (IV):
Figure imgf000081_0001
wherein B is a nucleic acid base and R4 is hydrogen atom or a protecting group.
2. A cyclobutane derivative according to Claim 1, wherein said nucleic acid base is a pyrimidine base or a purine base.
3. A cyclobutane derivative according to Claim 2,
wherein said pyrimidine base is
Figure imgf000081_0002
and said purine base is /
Figure imgf000081_0003
wherein Y represents hydrogen atom, or lower alkyl group,
Y 2 represents hydrogen atom, halogen atom or ammo group,
Y 3 represents hydrogen atom or amino group, and Y4
represents hydrogen atom or amino group.
4. A cyclobutane derivative according to Claim 1, wherein the substituents in formula (IV) are sterically so configured that substituent B and its adjacent hydroxy¬ methyl group are in a trans relation and the hydroxymethyl group adjacent to B and the other hydroxymethyl group are in a trans relation.
5. A cyclobutane derivative according to Claim 1, wherein the steric configuration of the substituents in formula (IV) is (1R,2R,3S).
6. A cyclobutane derivative according to Claim 1 to Claim 3, wherein B is adenine or guanine.
7. A cyclobutane derivative according to Claim 1, wherein the protecting group of R is an ester type protecting group or an ether type protecting group.
8. A cyclobutane derivative according to Claim 5,
4 wherein the protecting group of R is an acetyl group.
9. A cyclobutane derivative represented by the following general formula (III) :
Figure imgf000082_0001
(wherein R , taken individually, represents an alkyl group having 1 to 5 carbon atoms or an aralkyl group or. taken in conjunction of two R groups, represents a cyclic alkylene group having 2 to 3 carbon atoms; R represents hydrogen atom, alkyl group having 1 to 5 carbon atoms, protected hydroxyalkyl group or protected carboxyl
3 group; R represents hydrogen atom, alkyl group having 1 to 5 carbon atoms, alkoxy group having 1 to 5 carbon atoms or aralkyloxy group; A represents straight or branched chain alkylene group having 2 to 5 carbon atoms; Y represents oxygen atom or sulfur atom; and Z represents substituted or unsubstituted methylene group, oxygen atom or sulfur atom.
10. An antiviral agent comprising, as its active ingredient, a cyclobutane derivative represented by the following general formula (IV):
Figure imgf000083_0001
wherein B represents nucleic acid base, and R represents hydrogen atom or a protecting group.
11. An antiviral agent according to Claim 10, wherein said virus is Herpes Simplex Virus,
Cytomegalovirus, B Hepatitis Virus or Immunodeficiency
Virus.
12 . A pharmaceutical use of a cyclobutane derivative represented by the fol lowing general formula (IV) :
Figure imgf000084_0001
4 wherein B represents nucleic acid base, and R represents hydrogen atom or a protecting group.
13. A use of 9-[ (1R,2R,3S)-2,3-Bis(hydroxymethyl)- eyelobutane-1-yl]-guanine for treatment of diseases caused by DNA virus.
14. The use according to claim 13, wherein the DNA virus is Herpes Simplex Virus, Cytomegalovirus or B Hepatitis Virus.
15. A use of 9-[(1R,2R,3S)-2,3-Bis(hydroxymethyl)- cyclobutane-1-yl]-adenine for treatment of diseases caused by a virus.
PCT/JP1989/001190 1988-11-22 1989-11-22 Novel cyclobutane derivative and process for producing same WO1990005730A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
GB9015942A GB2232669B (en) 1988-11-22 1989-11-22 Novel cyclobutane derivative and process for producing same
DE19893991368 DE3991368T1 (en) 1989-11-22 1989-11-22 NEW CYCLOBUTAN DERIVATIVE AND METHOD FOR THE PRODUCTION THEREOF
SE9002445A SE501370C2 (en) 1988-11-22 1990-07-16 New cyclobutane derivative and process for preparation thereof

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
JP63/295135 1988-11-22
JP29513588 1988-11-22
JP4303689 1989-02-27
JP1/43036 1989-02-27
JP1/158223 1989-06-22
JP15822389 1989-06-22

Publications (2)

Publication Number Publication Date
WO1990005730A2 true WO1990005730A2 (en) 1990-05-31
WO1990005730A3 WO1990005730A3 (en) 1990-09-07

Family

ID=27291425

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP1989/001190 WO1990005730A2 (en) 1988-11-22 1989-11-22 Novel cyclobutane derivative and process for producing same

Country Status (5)

Country Link
ES (1) ES2049678A6 (en)
GB (1) GB2232669B (en)
NL (1) NL8921278A (en)
SE (1) SE501370C2 (en)
WO (1) WO1990005730A2 (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4177348A (en) * 1977-12-13 1979-12-04 United States Government Carbocyclic analogs of cytosine nucleosides
EP0159264A2 (en) * 1984-04-10 1985-10-23 Merck & Co. Inc. Antiviral compounds
EP0184473A1 (en) * 1984-10-26 1986-06-11 Merck & Co. Inc. Regioselective synthesis of 9-substituted purine acyclonucleoside derivatives
EP0291229A2 (en) * 1987-05-11 1988-11-17 Merck & Co. Inc. 9(2-(hydroxymethyl) cycloalkylmethyl)guanines

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU622926B2 (en) * 1988-09-09 1992-04-30 Nippon Kayaku Kabushiki Kaisha Pyrimidine or purine cyclobutane derivatives

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4177348A (en) * 1977-12-13 1979-12-04 United States Government Carbocyclic analogs of cytosine nucleosides
EP0159264A2 (en) * 1984-04-10 1985-10-23 Merck & Co. Inc. Antiviral compounds
EP0184473A1 (en) * 1984-10-26 1986-06-11 Merck & Co. Inc. Regioselective synthesis of 9-substituted purine acyclonucleoside derivatives
EP0291229A2 (en) * 1987-05-11 1988-11-17 Merck & Co. Inc. 9(2-(hydroxymethyl) cycloalkylmethyl)guanines

Also Published As

Publication number Publication date
SE9002445D0 (en) 1990-07-16
GB9015942D0 (en) 1990-09-05
NL8921278A (en) 1990-10-01
GB2232669B (en) 1992-11-25
GB2232669A (en) 1990-12-19
SE9002445L (en) 1990-07-16
WO1990005730A3 (en) 1990-09-07
SE501370C2 (en) 1995-01-23
ES2049678A6 (en) 1994-04-16

Similar Documents

Publication Publication Date Title
EP0358154B1 (en) Novel cyclobutane derivative and process for producing same
JP2694999B2 (en) Bis (hydroxymethyl) cyclobutyl purines and pyrimidines
US5059690A (en) Purinyl tetrahydrofurans
Harnden et al. Synthesis and antiviral activity of 9-alkoxypurines. 1. 9-(3-Hydroxypropoxy)-and 9-[3-hydroxy-2-(hydroxymethyl) propoxy] purines
EP0141927A2 (en) Antiviral guanine derivatives
Zhao et al. Asymmetric synthesis of (1'S, 2'R)-cyclopropyl carbocyclic nucleosides
NO168036B (en) ANALOGUE PROCEDURE FOR THE PREPARATION OF THERAPEUTIC ACTIVE PURINYL AND PYRIMIDINYL CYCLOBUTANES.
KR940010033B1 (en) Process for preparing purine compounds having antivirus activity
US4965270A (en) Purine derivatives
EP0330992A2 (en) Novel cyclobutane Derivatives, processes for their preparation and pharmaceutical compositions comprising them
EP0394893B1 (en) Purinyl and pyrimidinyl tetrahydrofurans
WO1990005730A2 (en) Novel cyclobutane derivative and process for producing same
US5374625A (en) Adenine and guanine derivatives for the treatment of hepatitis virus infections
JP2577640B2 (en) New cyclobutane derivatives
JP2632646B2 (en) Novel cyclobutane derivative and production method thereof
EP1210347A1 (en) Carbocyclic nucleosides and process for obtaining such
JPH07126282A (en) New thionucleoside derivative
JP2888333B2 (en) Antiviral agent
EP0464769B1 (en) Purinyl and pyrimidinyl tetrahydrofurans
JP2783531B2 (en) Anticancer drug
HU216827B (en) Process for producing new (1r,2r,3s)-cyclobutyl purine and pirimidine derivatives and pharmaceutical compositions containing the same
JPH09249690A (en) 4'-thioarabninopurine nucleoside
US5272152A (en) Purinyl and pyrimidinyl tetrahydrofurans
US5145960A (en) Pyrimidinyl tetrahydrofurans
JPH03223264A (en) Novel cyclopentane derivative and its preparation

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): DE ES GB NL SE

ENP Entry into the national phase in:

Ref document number: 9050027

Country of ref document: ES

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 009050027

Country of ref document: ES

Ref document number: P009050027

Country of ref document: ES

AK Designated states

Kind code of ref document: A3

Designated state(s): DE ES GB NL SE

RET De translation (de og part 6b)

Ref document number: 3991368

Country of ref document: DE

Date of ref document: 19910110

WWE Wipo information: entry into national phase

Ref document number: 3991368

Country of ref document: DE

WWG Wipo information: grant in national office

Ref document number: 9050027

Country of ref document: ES

Kind code of ref document: A

WWX Former pct application expired in national office

Ref document number: 9050027

Country of ref document: ES

Kind code of ref document: A